+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

List of PDF Full Texts available from EurekaMag Chapter 35490

Chapter 35490 contains a list of PDF Full Texts available from EurekaMag.





D.S.lva, R.R.gina; D.O.iveira, T.T.ledo; Nagem, T.J.rge; Vieira, H.D.S.lva, 2002:
Pharmacologycal properties of natural dyes curcumin and norbixin

Somlyo, A.P.; Wu, X.; Walker, L.A.; Somlyo, A.V., 1999:
Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases

Lamounier Zepter, V.; Balzereit, D.; Baltas, L.G.; Morano, I., 2001:
Pharmacomechanical coupling in the absence of smooth muscle myosin, in visceral smooth muscle

Mehta, A.; Dodd, R.H., 2002:
Pharmacophore generation, development, and use in drug design Accelerated drug discovery through prediction of chemical reactivities

Song, M.; Breneman, C.M.; Zhuang, D.; Sukumar, N., 2002:
Pharmacophore identification and bioactivity prediction based on the TAE electronic conformation method

Bersuker, I.B., 2003:
Pharmacophore identification and quantitative bioactivity prediction using the electron-conformational method

Pae, A.N.m; Lee, I.Y.ung; Koh, H.Y.ong, 2003:
Pharmacophore mapping of a series of isoxazolylpiperazine inhibitors selectively acting on the dopamine D4 receptor

Chen, Q.; Li, J.; Maxwell, D.; Holland, G.; Dixon, R.; You, T., 2000:
Pharmacophore model for VLA4 antagonist

Kurogi, Y.; Güner, O.F., 2001:
Pharmacophore modeling and three-dimensional database searching for drug design using catalyst

de Groot, M.J.; Ekins, S., 2002:
Pharmacophore modeling of cytochromes P450

Ellman, J.A.; Choong, I., 2002:
Pharmacophore recombination for the identification of small molecule drug lead compounds

Good, A.C.; Mason, J.S.; Green, D.V.S.; Leach, A.R., 2001:
Pharmacophore-based approaches to combinatorial library design

Wang, S.; Sakamuri, S.; Enyedy, I.; Wang, J.; Kozikowski, A.P.; Tella, S.; Zaman, W.A.; Johnson, K.M., 2001:
Pharmacophore-based discovery and design of novel DAT inhibitors as potential therapy for the treatment of cocaine addiction

Reggio, P.H., 2003:
Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors

Pozzan, A.; Feriani, A.; Tedesco, G.; Capelli, A.M.ria, 2002:
Pharmacophoric 3D mill hashed fingerprints Add another dimension to your similarity searching

Barrios, A.M.; Craik, C.S., 2002:
Pharmacophoric profiling of proteolytic enzymes using novel lanthanide-based fluorogenic substrates

Kovarova, H.; Hajduch, M.; Halada, P.; Man, P.; Strnad, M., 2001:
Pharmacoproteomics Search for a new generation of anticancer drugs

Eliason, J.F.; Megyeri, A., 2003:
Pharmacoproteomics for fluoropyrimidine efficacy A new assay with potential for patient selection

Elger, C.E., 2003:
Pharmacoresistance: modern concept and basic data derived from human brain tissue

Ebert, U.; Wlaz, P.; Mcintyre, D.C.; Loescher, W., 2001:
Pharmacoresistance to phenytoin in two rat strains with different seizure susceptibility

Martin, N.E.; Read, K.A.; Martin, L.; Krishnaswami, S.; Wray, H.; Barrett, J., 2002:
Pharmacoscintigraphic assessment of the regional drug absorption of M100240 in healthy volunteers

Cass, L.M.; Brown, J.; Pickford, M.; Fayinka, S.; Newman, S.P.; Johansson, C.J.; Bye, A., 1999:
Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

Forrest, A.; Rayner, C.R.; Meagher, A.K.; Birmingham, M.C.; Schentag, J.J., 2000:
Pharmacostatistical modelling of hematologic effects of linezolid in seriously-III patients

Andujar Arias, M.M.; Nieto Pajares, J.F.; Hurtado Losanez, A.; D.A.cos Gutierrez, F., 2002:
Pharmacotherapeutic Guidebooks design in connection with the pharmacys management program Permanent update

Khafizyanova, R.K.; Borodin, Y.I.; Pratsuk, S.A., 2003:
Pharmacotherapeutic aspects of chronic fetoplacenthar insufficiency

van Riel, P.L.; Haagsma, C.J.; Furst, D.E., 2000:
Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis

Fontana, D.; Uema, S.; Sola, N., 2003:
Pharmacotherapeutic follow-up in hospital setting SWOT Analysis

Gertz, H.J., 2003:
Pharmacotherapeutic options in vascular dementia

Kubek, Michael, J., 2001:
Pharmacotherapeutic process and composition for central nervous system disorders

Kovacs, G., 2003:
Pharmacotherapeutic trends of bipolar disorders in Hungary

Dayan, C.M.; Lightman, S.L., 2002:
Pharmacotherapeutics and the endocrine system: blocking, replacing and exploiting nature's magic bullets

Chiu, C.S.; Rubin, P.A.D., 2004:
Pharmacotherapies and nonpharmacotherapies for orbital inflammatory diseases

Smith, I.E.; Quinnell, T.G., 2004:
Pharmacotherapies for obstructive sleep apnoea: where are we now?

Carroll, F.I.; Howell, L.L.; Kuhar, M.J., 1999:
Pharmacotherapies for treatment of cocaine abuse: preclinical aspects

Rogovik, A.L.; Chanoine, J-Pierre.; Goldman, R.D., 2010:
Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity

Kunisawa, J.; Nakagawa, S.; Mayumi, T., 2001:
Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development

Braden, G.A.; Rankin, K.M.; Young, T.M.; Hobbs, W.L.; Applegate, R.J., 2001:
Pharmacotherapy eliminates the need for temporary pacemakers during rotational atherectomy Follow-up of the BRAT study

Vague, P.; Halimi, S., 1999:
Pharmacotherapy for Non-Insulin-Dependent Diabetes Treatment Strategies and Principles

Kaplan,A.S.; Howlett,A., 2010:
Pharmacotherapy for anorexia nervosa

Bodell,L.P.; Devlin,M.J., 2010:
Pharmacotherapy for binge-eating disorder

Broft,A.; Berner,L.A.; Walsh,B.T., 2010:
Pharmacotherapy for bulimia nervosa

Wit, N.J.; Quartero, O.A.; Zuithoff, P.A.; Numans, M.E., 2001:
Pharmacotherapy for dyspepsia; analysis of prescription patterns

Abraham, W.; Suresh, D.P.; Wagoner, L.E.; Haas, G.J.; Nelson, C.; Bakker Arkema, R.G., 2000:
Pharmacotherapy for hyponatraemia in heart failure Effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan administered orally

Bichet, D.G.; Madore, F.; Cusson, J.; Arthus, M.F.ancoise; Lonergan, M.; Nelson, C.B.; Bakker Arkema, R.G., 1999:
Pharmacotherapy for hyponatremia in SIADH Effects of a new orally administered dual V1a/V2 vasopressin antagonist YM087

Abraham, W.T.; Suresh, D.P.; Wagoner, L.E.; Haas, G.J.; Mccord, J.; Rydzinski, S.; Nelson, C.B.; Bakker Arkema, R.G., 1999:
Pharmacotherapy for hyponatremia in heart failure Effects of a new dual V1A/V2 vasopressin antagonist YM087

Kuscu, N.Kemal, 2003:
Pharmacotherapy for nausea and vomiting in early pregnancy

Cole, S.; Smith, R.; Bisits, A., 2001:
Pharmacotherapy for preterm labour

Richter, B.; Neises, G.; Clar, C., 2002:
Pharmacotherapy for thyroid nodules. A systematic review and meta-analysis

Sims, T.Harris.; Fiore, M.C., 2002:
Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy?

Gross, S.S.; Jones, C.L., 2004:
Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity

Blanck, H.M.; Khan, L.K.ttel; Serdula, M.K., 2003:
Pharmacotherapy for weight loss Weight loss success and compliance with lifestyle recommendations

Romano, M.; Cuomo, A., 2004:
Pharmacotherapy of Helicobacter pylori-associated gastritis

Mann, K., 2004:
Pharmacotherapy of alcohol dependence: a review of the clinical data

Brower, K.J.; Kim, H.M.; Karam Hage, M.A.; Zucker, R.A.; Greden, J.F., 2003:
Pharmacotherapy of alcoholism and comorbid insomnia

Fassbender, K., 2003:
Pharmacotherapy of dementias

Maĭchuk, I.F., 1999:
Pharmacotherapy of eye infection

Guglietta, Antonio, 2004:
Pharmacotherapy of gastrointestinal inflammation

Veljaca, Marija, 2004:
Pharmacotherapy of inflammatory bowel disease Novel therapeutic approaches

Jennings, M.T.; Iyengar, S., 2001:
Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends

Martinovic, Z.; Milovanovic, M.; Buder, N.; Milic, S.; Jakovljevic, V., 2003:
Pharmacotherapy of migraine comorbid with epilepsy

Guy Grand, B., 2002:
Pharmacotherapy of obesity Historical perspective

Haynes, W.G.; Mark, A.L., 2002:
Pharmacotherapy of obesity: lessons from clinical trials in hypertension

Makarov, L.M., 2003:
Pharmacotherapy of pediatric cardiac arrhythmia

Alexandrovsky, Y.A., 1999:
Pharmacotherapy of psychic disorders

Styczynski, Tadeusz, 2002:
Pharmacotherapy of the neuropathic pain

Ferone, D.; Colao, A.; van der Lely, A.J.; Lamberts, S.W., 2000:
Pharmacotherapy or surgery as primary treatment for acromegaly?

L.P.ieur, E.; Bion, A.; Dionnet, F.; Morin, J.P.; Thuillez, C., 2000:
Pharmacotoxicological impact of diesel engine exhaust on lung tissue

D.A.ajo, F.J.; Montero, D.; Cacha, A., 2000:
Pharmacovigilance Goals and strategies

Sutton, D., 2003:
Pharmacovigilance Why look for problems?

Magaeva, V.; Lissitchkov, T., 2000:
Pharmacovigilance and plasma products in Bulgaria

Nishiyama, P.; Bonetti, M.D.F.tima D.S.uza; Bohm, A.C.rolina Feitoza; Margonato, F.B.rdini, 2002:
Pharmacovigilance at Regional University Hospital in Maringa, PR

Cuchi, T.; Bartolome, M., 2000:
Pharmacovigilance in community pharmacies

Meyboom, R.H.; Egberts, A.C.; Gribnau, F.W.; Hekster, Y.A., 1999:
Pharmacovigilance in perspective

Alesso, L.; Montrull, H.; Segura, A.; Lizzio, S., 2000:
Pharmacovigilance in public hospitals in Cordoba, Argentina

McNamee, D., 1999:
Pharmacovigilance into 2000

Simiand Erdocian, E.; Bagheri Charabiani, H.; Magnaval, J.F.ancois; Montastruc, J.L.uis, 2000:
Pharmacovigilance of antihelmintics A review of the French pharmacovigilance database

Hernandez, C.; Duran, R.; Jara, J.; Moncada, I.; Subira, D., 2003:
Pharmacovigilance study in 3,684 patients diagnosed of BPH and treated with doxazosine GITS

Royer, R.J., 1999:
Pharmacovigilance up to date

Gonzalez, D.Posada, Francisco, 2003:
Pharmacy From Physics to Biology On the existence of phantoms

Afifi, F.U.; Taha, M.O., 2000:
Pharmacy and the utilization of CAL and IT

Dunham, D.B.; Meek, P.D.; Hoffman, J.M.; Reichelderfer, M., 2003:
Pharmacy audit of an evidence-based clinical practice guideline for the use of parenteral pantoprazole

Salvaggio, C.A.; Pandit, S.; Mccolgan, M.D., 2002:
Pharmacy availability of activated charcoal vs ipecac syrup

Lipton, H.L.; Kreling, D.H.; Collins, T.; Hertz, K.C., 1999:
Pharmacy benefit management companies: dimensions of performance

Simpson, D.D.; Jones, S.; Hudson, T.J.; Sawyer, J.K.; Mills, M.E.; Falls, L.J.; Golden, W.E., 1999:
Pharmacy claims rates for the asthmatic Medicaid population in a rural state

Ramos, M.C.nha; Gobbato, R.O.so; D.R.cha, F.C.veira; D.L.ca, G.; Tierling, F.; Vissoky, J.; Cestari, T., 2002:
Pharmacy clerks prescription practices for patients with sexually transmitted diseases in Porto Alegre, Brazil

Seifert, S.A.; Jacobitz, K.; Scheer, A., 2002:
Pharmacy compounding and order-of-magnitude errors

Jahansouz, F.; Lamott, J.; Stephanson, L.G.; Mehta, R.L., 2001:
Pharmacy cost analysis of citrate anticoagulation for continuous renal replacement therapy

Figg, W.D.; Cox, M.C., 2003:
Pharmacy education: back to the basics?

Foote, R.W.; Young, R., 1999:
Pharmacy label and record system and method

Hopkins, Cyrus, C., 1999:
Pharmacy service

Budarin, S.S.; Gogotova, M.V., 2000:
Pharmacy service in some European countries

Dierschke, B.; Berge, C., 2003:
Pharmacy service interventions in pediatric inner city asthma

Hunter, H.; Crouch, B.I.; Caravati, E.M., 2003:
Pharmacy students as poison prevention educators

Sewchok, Dolores, R., 2002:
Pharmacy technician training program profile Bidwell Training Center

Van Bergen, J.E.A.M.; Peerbooks, P.G.H.; Spangenberg, A.C., 2001:
Pharmacy-assisted active case-finding of CT-infections in a family practice in Amsterdam using mailed home-collected urine-samples

Santos, M.R.; Costa, S.; Andre, O.; Matias, L., 2003:
Pharmacy-based diabetes management programme in Portugal Preliminary results of a pilot intervention

Kircher, T.; Erb, M.; Grodd, W.; Leube, D., 2003:
Pharmako-FMRT in Alzheimers dementia

Baum, R.P.; Calcagni, M.; Dimitrakopoulou Strauss, A.; Strauss, L.G., 2003:
Pharmakokinetic analysis of O-2- Fluorethyl-L-Tyrosin by dynamic PET in the differential diagnosis of malignant gliomas

Daru, J.A.; Fedczyna, T.; Ngai, K.N.; Pachman, L.M., 2000:
Pharmakokinetic studies show decreased absorption of oral methylprednisolone compared with intravenous methylprednisolone in rheumatic disease patients with active vasculitis

Alieva, E.I.; Tsvetkova, L.N., 2000:
Pharmakotherapy of pediatric bowel motility disorders

Men, A.; Venitz, J., 2004:
Pharmaokinetics of intraveneous scopolamine plus physostigmine in healthy elderly male and female volunteers

Robins, Terry, 2000:
Pharmavirogenomics of HIV

Reid, J.K.; Paus Jenssen, L.; Marciniuk, D.D.; Hoeppner, V.H., 2000:
Pharmcokinetics of anti-tuberculosis medications, administered by percutaneous gastrojejunostomy tube

Keefer, C.E.; Bigham, E.C.; Young, S., 2001:
Pharmcophore identification using massive distributed computing

Alli, Z.; Sardana, R.K.; Pierre, B.; Andonov, A.; Robert, L.S.; Schernthaner, J.P.; Porter, S.L.; Dudani, A.K.; Ganz, P.R.; Tackaberry, E.S.; Altosaar, I., 2002:
Pharming vaccines for hepatitis and cytomegalovirus Towards the development of multivalent and subunit vaccines for oral delivery of antigens

Freedman, J.E.; Pezzullo, J.C.; Abernethy, D.R.; Jordan, R.E.; Frederick, B.; Mascelli, M.A.n, 1999:
Pharmocodynamic profile of acute readministration of abciximab

Arzamastsev, A.P.; Kondratenko, S.N.; Starodubtsev, A.K.; Blinkov, I.L.; Svetyi, L.I., 2003:
Pharmocokinetic properties of certain cardiovascular preparations in patients with inflammatory large bowel disease

Kharasch, S.J.; Ryan, K.M.; Metha, S.D.; Capozzi, M.; Zuckerman, B., 2003:
Pharmocologic interventions for selected procedures performed in an emergency department

Boomhower, M.S.; Donnely, R.; Young, R.S.; Witten, M.L., 2000:
Pharmokinetics of 3H Sar9 Met 11-substance P in mice

Kobayashi, Sadao, 2001:
Pharyngeal cell masses of Xenopus laevis at early stage of development

Thurnheer, R., 1999:
Pharyngeal cross-sectional area and compliance in normal males and females

Chen Bao Yuan; H.Q.an Ying, 2003:
Pharyngeal dilator muscles and abstructive sleep apnea hypoventilation syndrome

Kawamura, O.; Aslam, M.; Rittmann, T.; Hofmann, C.; Shaker, R., 2003:
Pharyngeal distribution of non acidic and acidic gastric refluxate a 24 hour simultaneous ambulatory impedance and ph recording

Matz, S.P.; Northcutt, R.G., 1999:
Pharyngeal endoderm Not chordamesoderm induces epibranchial placodes in axolotls to form neurons

Farrell, M.; Burch, J.; Kumiski, D.; Stadt, H.; Godt, R.; Creazzo, T.; Kirby, M., 1999:
Pharyngeal endoderm produces a factor that suppresses development of myocardial calcium transients

Jalil, S.; Tutuian, R.I.; Castell, D.O., 2002:
Pharyngeal function testing using combined multichannel intraluminal impedance and manometry Pilot study

Traub, S.J.; Hoffman, R.S.; Nelson, L.S., 2001:
Pharyngeal irritation after eating cooked tarantula

Ferry Graham, L.A.; Wainwright, P.C.; Near, T.J., 2003:
Pharyngeal jaw form, function, and evolution in the Labroidei

Bullock, Andrea, 2001:
Pharyngeal mastication in scarid fishes A comparative anatomical approach

Brain, A.I.; Verghese, C.; Kapila, A., 2000:
Pharyngeal mucosa pressures

Brimacombe, J.; Costa e Silva, L., 2003:
Pharyngeal necrosis with the laryngeal mask airway

Omelanczuk, P.E.; Eubanks, T.R.; Horgan, S.; Maronian, N.; Hillel, A.; Pope, C.E.; Pellegrini, C.A., 2000:
Pharyngeal pH measurements in patients with laryngeal symptoms prior to and during proton pump inhibitor therapy

Eubanks, T.R.; Omelanczuk, P.E.; Maronian, N.; Hillel, A.; Pope, C.E.; Pellegrini, C.A., 2000:
Pharyngeal pH monitoring in 200 patients with suspected laryngeal reflux

Ylitalo, R.H.; Hammarlund, B.; Lindgren, E.; Ramel, S., 2002:
Pharyngeal reflux is under diagnosed in patients with heartburn

Shaker, R.; Gu, C.; Simuncak, C.; Kern, M.K.; Massey, B.T.; Arndorfer, R.C., 2001:
Pharyngeal water stimulation induces gastric fundic relaxation

Pan, C-L.; Shun, C-T.; Susuki, K.; Yuki, N.; Hsieh, S-T., 2004:
Pharyngeal-brachial palsy after cytomegalovirus colitis

Migliore, M.; Arcerito, M.; Giuliano, R.; Gangi, S.; Basile, F.; Deodato, G., 2000 :
Pharyngo-esophageal dysphagia as a clinical presentation of esophageal achalasia

Bursey, C.R.; Goldberg, S.R., 1999:
Pharyngodon oceanicus sp n from the oceanic gecko, Gehyra oceanica of the Pacific Islands

Desuter, G.; Schmitz, S.; Jamar, F.; Weynand, B.; Rahier, J.; Hamoir, M., 2004:
Pharyngoesophagolaryngeal metastases of medullary thyroid carcinoma. A case report

Omura, K.; Kanehira, E.; Kawakami, K.; Maeda, K.; Ishiguro, K.; Ishikawa, N.; Ohta, K.; Watanabe, G., 2002:
Pharyngolaryngoesophagectomy for well-differentiated papillary thyroid carcinoma widely invading the upper aerodigestive tract

Portereiko, M.F.; Mango, S.E., 2001:
Pharynx tubulogenesis during Caenorhabditis elegans development

Cifelli, R.L.; Dykes, T.D., 2001:
Phascolotheridium, a new name for Phascolodon Simpson, 1925 preoccupied by Phascolodon Stein, 1859

Figlin, R.; Belldegrun, A.; Crawford, J.; Lohner, M.; Roskos, L.; Yang, X.D.; Foon, K.A.; Schwab, G.; Weiner, L., 2002:
Phase 1 clinical trial of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody for patients with advanced cancer

Yoshiaki, M.; Sasatomi, T.; Ogata, Y.; Yanama, H.; Shirouzu, K.; Matsunaga, K.; Itoh, K., 2001:
Phase 1 clinical trial of SART3 peptide cancer vaccine for colorectal cancer patients

Bander, N.H.; Nanus, D.; Bremer, S.; Smith Jones, P.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S.; Liu, H.; Moy, P.; Xia, J.; Kim, S.; Navarro, V., 2000:
Phase 1 clinical trial targeting a monoclonal antibody to the extracellular domain of prostate specific membrane antigen in hormone-independent patients

Vllabhajosula, S.; Malhi, N.; Hamacher, K.A.; Kostakoglu, L.; Bander, N.H.; Goldsmith, S.J., 2003:
Phase 1 dose escalation trial with 90Y-DOTA-J591 antibody Can hematologic toxicity be predicted based on bone marrow absorbed radiation dose?

Brown, G.L.; White, R.J.; Taubel, J., 2000:
Phase 1 dose optimization study for V-echinocandin

Feldman, E.J.; Roboz, G.J.; Allen Bard, S.L.; Awofisayo, S.; Schuster, M.; Shore, T.; Jolivet, J.; Silver, R.T., 2003:
Phase 1 evaluation of troxacitabine administerd by continuous infusion in patients with refractory acute myeloid leukemia

Vale, P.R.chard; Losordo, D.W.; Milliken, C.E.; Fortuin, D.; Symes, J.F.; Schatz, R.A.; Isner, J.M.; Kuntz, R.E., 2001:
Phase 1 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer utilizing catheter delivery in patients with chronic myocardial ischemia

Pierce, M.A.; Ellis, R.D.; Martin, L.B.; Malkin, E.; Tierney, E.; Miura, K.; Fay, M.P.; Marjason, J.; Elliott, S.L.; Mullen, G.E.D.; Rausch, K.; Zhu, D.; Long, C.A.; Miller, L.H., 2010:
Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

Dunkle, L.M.; Oshana, S.; Dickson, J.; Cheng, Y.; Rice, W.G., 2001:
Phase 1 safety and pharmacokinetics of ACH-126,443, a potent anti-HIV and HBV nucleoside

Mzayek, F.; Deng, H.; Liu, H.; Mather, F.J.; Mushatt, D.M.; Melek, B.; Lertora, J.J.L.; Krogstad, D.J., 2003:
Phase 1 studies of AQ13 An aminoquinoline active against chloroquine-resistant Plasmodium falciparum Dose adjustment based on pharmacokinetic comparison with chloroquine

Burris, H.; Shipley, D.; Greco, A.; Jones, S.; Bolton, M.G., 2003:
Phase 1 studies of CT-2103 in patients with non small cell lung cancer and with advanced malignancies

Tsujinaka, T.; Narahara, H.; Takiuchi, H.; Furukawa, H.; Taguchi, T., 2002:
Phase 1 study of CPT-11 plus S-1 for patients with metastatic gastric cancer

Nemunaitis, J.; Bolton, M., 2003:
Phase 1 study of CT-2103/carboplatin in patients with solid tumors

Skubitz, K.; Kudelka, A.; Bolton, M.G., 2003:
Phase 1 study of CT-2103/cisplatin in patients with solid tumors

Gelmon, K.A.; Eisenhauer, E.; Renyo, L.; Hirte, H.; Britten, C.; Lee, U.; Fisher, B.; Ayers, D.; D'aloisio, S.; Stafford, S.; Hamilton, M.; Ptaszynski, M., 2000:
Phase 1 study of NX 211 given as an intravenous infusion on days 1, 2, and 3 every weeks in patients with solid tumors- An NCIC clinical trials group study

Wright, T.L.; Tong, M.J.; Hsu, H.H., 1999:
Phase 1 study of a potent adjuvanted hepatitis B vaccine for therapy of chronic hepatitis B

Sadozye, A.H.; Samuel, L.M.; Mcmahon, L.; Mcdonald, A.C., 2003:
Phase 1 study of mitomycin-C continuous infusion 5-FU chemoradiation in locally advanced rectal cancer

Bolwell, B.; Vredenburgh, J.; Overmoyer, B.; Gilbert, C.; Chap, L.; Menchaca, D.M.; Cruickshank, S.; Glaspy, J., 2000:
Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor in breast cancer patients after autologous peripheral blood progenitor cell transplantation

Farrugia, D.; Tischkowitz, M.; Ford, H.E.R.; Kellaway, J.; Joel, S.; Mitchell, F.; Noyce, C.; Jackman, A.; Aherne, G.W.; Slevin, M.L., 1999:
Phase 1 study of raltitrexed given every 14 days

Senzer, N.; Cunningham, C.; Rosemurgy, A.; Mani, S.; Guha, C.; Chu, K.; Gillen, M.; Rasmussen, H.; Hanna, N.; Nemunaitis, J., 2003:
Phase 1 study of selective radiosensitization with TNFerade, a radiation-inducible alpha tumor necrosis factor gene transfer vector Focus on a subset analysis of 6 patients with concurrently irradiated control lesions

Valkema, R.; Kvols, L.; Jamar, F.; Bakker, W.H.; Smith, C.; Krenning, E.P.; Pauwels, S., 2002:
Phase 1 study of therapy with 90Y-SMT487 in patients with somatostatin receptor positive tumors

Morales, A.; Voccia, I.; Pommerville, P.; Steinhoff, G.; Riviere, M., 2004:
Phase 1 study with mycobacterial cell wall extract and hyaluronic acid for the intraprostatic treatment of localised prostate cancer

Harrow, S.; Papanastassiou, V.; Brown, S.M.; Fraser, M.; Rampling, R., 2002:
Phase 1 trial of herpes simplex virus, HSV1716 following injection into brain adjacent to tumour in patients with primary malignant glioma

Hesdorffer, C.; Ayello, J.; Ward, M.; Kaubisch, A.; Bank, A.; Antman, K., 2000:
Phase 1 trial of retroviral-mediated transfer of the human MDR-1 in patients undergoing high-dose chemotherapy and autologous stem cell transplantation

Goldwater, R.; Boileau, F.; Lee, S.M.; Chung, G.J.; Kim, D.Y.; Cho, K.D., 1999:
Phase 1, randomized, parallel, placebo-controlled, safety, tolerance and pharmacokinetic study of multiple dose of IY-81149 in fasting male volunteers

Rowinsky, E.; Schwartz, G.; Dutcher, J.; Vogelzang, N.; Gollob, J.; Thompson, J.; Bukowski, R.; Figlin, R.; Lohner, M.; Roskos, L.; Hwang, C.C.; Foon, K.A.; Schwab, G., 2002:
Phase 2 clinical trial in renal cell cancer evaluating the safety and effectiveness of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody

Hopkins, W.J.; Uehling, D.T.; Balish, E., 2000:
Phase 2 clinical trial of a vaginal mucosal vaccine for recurrent urinary tract infections in adult women

Elkahwaji, J.E.; Hopkins, W.J.; Leverson, G.E.; Uehling, D.T., 2002:
Phase 2 clinical trial of a vaginal mucosal vaccine for recurrent urinary tract infections in adult women Updated interim analysis

Foulks, G.; Sall, K.; Greenberg, M.; Tauber, J.; Donshik, P.; Berdy, G.; Sylvester, R.; Yerxa, B.; Crockett, S.; Kellerman, D., 2001:
Phase 2 dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y2 agonist, in patients with dry eye

Eftekharpour, E.; Juurlink, H.J., 2000:
Phase 2 enzyme induction in astrocytes increases neuronal peroxide scavenging abilities

Haley, E.Clarke, 2001:
Phase 2 experience with intravenous thrombolytic therapy for acute ischemic stroke

Clements Jewery, H.; Curtis, M.J., 2002:
Phase 2 ischaemia-induced ventricular fibrillation in the rat isolated blood-perfused heart

Lankipalli, R.S.; Joshi, A.; Yan, G.X.n; Wu, Y.; Liu, T.; Kowey, P.R., 2002:
Phase 2 reentry initiates the onset of ventricular fibrillation during early acute myocardial ischemia

Redfern, C.; Schulz, J.; Burris, H.; Bolton, M.G., 2003:
Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen

Bodkin, D.; Neubauer, M.; Bolton, M.G., 2003:
Phase 2 study of first line chemotherapy using CT-2103 in patients with non-small-cell lung cancer who are 69 years of age or who have performance status =2

Brizel, D.M.; Le, Q.T.; Rosenthal, D.; Meredith, R.; Brizel, H.E.; Heard, R.; Yao, B.; Eng, T.; Sailer, S.; Chen, Y.; Murphy, B.; Mendenhall, W., 2002:
Phase 2 study of recombinant human keratinocyte growth factor in head and neck cancer treated with standard or hyperfractionated irradiation and concurrent chemotherapy

Lipton, A.; Berenson, J.; Knight, R.; Hu, G.; Levy, E., 1999:
Phase 2 trial of Zoledronate vs Pamidronate in multiple myeloma and breast cancer

Mohler, E.R.; Klugherz, B.; Goldman, R.; Fishman, A.P.; Wade, M.; Sehgal, C.M., 1999:
Phase 2 trial of a novel prostacyclin analogue, UT-15, in patients with severe intermittent claudication

Friedenberg, W.R.; Rue, M.; Dalton, W.; Schiffer, C.A.; Shustik, C.; Cella, D.; Sonneveld, P.; Greipp, P.R.; Kyle, R., 2003:
Phase 3 Study of the multi-drug resistant modulator PSC-833 in relapsing or refractory multiple myeloma An intergroup study led by ECOG

Lindberg, J.S.; Culleton, B.; Wong, G.; Borah, M.F.; Clark, R.V.; Shapiro, W.B.; Roger, S.D.; Husserl, F.E.; Klassen, P.S.; Guo, M.D.; Albizem, M.B.; Coburn, J.W., 2003:
Phase 3 experience with cinacalcet HCl in hemodialysis and peritoneal dialysis patients with secondary HPT

Calais, F.; Bono, A.; Whealan, P.; Brausi, M.; Marques, Q.A.; Portilho, J.; Kirkali, Z.; Calais, F.M.; Seug, 2004:
Phase 3 study of intermittent MAB versus continuous MAB international cooperative study

Block, G.A.; Martin, K.J.; Turner, S.A.; Avram, M.M.; Hercz, G.; Abu Alfa, A.K.; Coyne, W.G.; Cohen, R.M.; Moe, S.M.; Mccary, L.C.; Olson, K.A.; Goodman, W.G., 2003:
Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCl in hemadialysis patients with secondary hyperparathyroidism

Holman, P.; Bashey, A.; Carrier, E.; Corringham, S.; Zhong, R.; Mason, J.; Ball, E.D., 2002:
Phase I Dose Escalation Study of a Single Dose of Anti-CD33 x Humanized Murine Anti-FcgammaRI Bispecific Antibody in Patients with Relapsed Acute Myeloid Leukemia

Cortes, J.E.; Estey, E.; Giles, F.; O'brien, S.; Keating, M.; Mcconkey, D.; Wright, J.; Schenkein, D.; Kantarjian, H., 2002:
Phase I Study of Bortezomib , a Proteasome Inhibitor, in Patients with Refractory or Relapsed Acute Leukemias and Myelodysplastic Syndromes

Jeha, S.; Gandhi, V.; Chan, K.W.h; Mcdonald, L.; Ramirez, I.; Rytting, M.E.; Madden, R.; Keating, M.J.; Plunkett, W.J.; Kantarjian, H., 2002:
Phase I Study of Clofarabine in Pediatric Leukemia

Hegde, U.; White, T.; Stetler Stevenson, M.; Marti, G.; Janik, J.; Pittaluga, S.; Kingma, D.; Steinberg, S.; Cheson, B.; Jaffe, E.S.; Wilson, W.H., 2002:
Phase I Study of Combination Rituximab and Apolizumab Monoclonal Antibody Therapy in Previously Treated B-Cell Lymphoma and Chronic Lymphocytic Leukemia

List, A.F.; Deangelo, D.; Brien, S.O.; Cortes, J.; Wilson, J.; Sugrue, M.M.; Zhu, Y.; Statkevich, P.; Baum, C.; Zaknoen, S., 2002:
Phase I Study of Continuous Oral Administration of Lonafarnib in Patients with Advanced Hematologic Malignancies

Friedberg, J.W.; Neuberg, D.; Bendell, C.; Miyata, S.; Mccauley, M.; Fisher, D.C.; Takvorian, T.; Canellos, G.P., 2002:
Phase I Study of Gemcitabine Added to Doxorubicin, Bleomycin, and Vinblastine for the Treatment of De Novo Hodgkins Disease Increased Pulmonary Toxicity Compared with ABVD

Saito, N.G.; Dawson, L.A.; Eisbruch, A.; Ratanatharathorn, V.; Uberti, J.P.; Adams, P.T.; Silver, S.M.; Ayash, L.J.; Reynolds, C.M.; Schipper, M.J.; Lichter, A.S., 2002:
Phase I Study of Involved Field Radiation Therapy Preceding High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High Risk Hodgkins Disease and Non-Hodgkins Lymphoma

Apostolidou, E.; Garcia Manero, G.; Cortes, J.; Thomas, D.; Andreeff, M.; Keating, M.; Tallman, M.; Kantarjian, H.; Giles, F., 2002:
Phase I Study of OSI-211, a Novel Liposomal Topoisomerase 1 Inhibitor, in Patients with Refractory Leukemia

Lum, B.L.; Srinivas, S.; Beck, J.T.; Vesole, D.H.; Magnuson, D.; Largey, M.; Valone, F.; Sayre, P.H., 2002:
Phase I Study of Oral Gallium Maltolate in Patients with Hematologic Malignancies

Bartlett, N.L.; Younes, A.; Carabasi, M.A.; Espina, B.; Dipersio, J.F.; Schliebner, S.D.; Siegall, C.; Sing, A.P., 2002:
Phase I Study of SGN-30, a Chimeric Monoclonal Antibody , in Patients with Refractory or Recurrent CD30 + Hematologic Malignancies

Alvarado, Y.; Brown, R.; Dipersio, J.; Verstovsek, S.; Cortes, J.; O'brien, S.; Sznol, M.; Kantarjian, H.; Fracasso, P.; Giles, F., 2002 :
Phase I Study of Triapine , a Novel Ribonucleotide Reductase Inhibitor , in Patients with Refractory Hematologic Malignancies

Hori, A.; Kami, M.; Kim, S.W.n; Nakagawa, T.; Makimoto, A.; Nakai, K.; Ando, T.; Saito, T.; Kanda, Y.; Mineishi, S.; Tanosaki, R.; Fujimoto, H., 2002:
Phase I Trial of Allogeneic Reduced-Intensity Stem Cell Transplantation for Patients with Metastatic Renal Cell Cancer

Roberts, J.D.; Feldman, E.J.; Smith, M.R.; Grant, S., 2002:
Phase I Trial of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkins Lymphoma

Roboz, G.J.; List, A.F.; Giles, F.; Rae, P.E.; Dugan, M.; Greenberg, J.; Osama, S.; Schuster, M.W.; Laurent, D.; Feldman, E.J., 2002:
Phase I Trial of PTK787/ZK 222584, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Marcucci, G.; Bruner, R.J.; Binkley, P.F.; Xiao, J.; Chan, K.K.; Parthun, M.; Davis, M.; Fischer, B.; Shank, R.; Moran, M.; Byrd, J.C.; Grever, M., 2002:
Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide in Acute Myeloid Leukemia

Bruner, R.J.; Marcucci, G.; Binkley, P.; Xiao, J.; Chan, K.; Parthun, M.; Davis, M.; Fischer, B.; Shank, R.; Moran, M.; Grever, M.; Byrd, J.C., 2002:
Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide in Fludarabine Refractory Chronic Lymphocytic Leukemia

Karp, J.E.; Greer, J.; Gojo, I.; Takebe, N.; Tidwell, M.; Braganza, M.; Sznol, M., 2002:
Phase I Trial of the Ribonucleotide Reductase Inhibitor 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone in Adults with Refractory Myeloid Malignancies

Eisenhauer, E.A., 2000:
Phase I and II evaluation of novel anticancer agents Are response and toxicity the right endpoints?

Chen, L.T.; Chao, Y.; Yao, T.J.; Huang, J.D.; Chang, J.Y.; Chin, Y.H.; Chuang, T.R.; Reed, E.; Whang Peng, J.; Liu, T.W., 2002:
Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma

Feun, L.; Modiano, M.; Lee, K.; Mao, J.; Marini, A.; Savaraj, N.; Plezia, P.; Almassian, B.; Macdonald, S., 2001:
Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone using a single intravenous dose schedule

Faivre, S.; Raymond, E.; Gatineau, M.; Buthaut, X.; Boige, V.; Mekhaldi, S.; Pautier, P.; Ducreux, M.; Camboni, G.; Armand, J.P., 1999:
Phase I and pharmacokinetic study of BBR 2778

Faivre, S.; Raymond, E.; Gatineau, M.; Buthaut, X.; Boige, V.; Bernareggi, A.; Rixe, O.; Mekhaldi, S.; Pautier, P.; L.C.evalier, T.; Ducreux, M.; Escudier, B.; Camboni, G.; Armand, J.P., 1999:
Phase I and pharmacokinetic study of BBR 2778, a novel azaanthracenedione, in patients with advanced solid tumors

Dittrich, C.; Dumez, H.; Calvert, H.; Hanauske, A.R.; Ravic, M.; Faber, M.; Van Houten, T.; Wanders, J.; Fumoleau, P., 2000:
Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single IV infusion, weekly X 4, q 6 weeks

Raymond, E.; Huinink, W.W.T.n Bokkel; Taieb, J.; Beijnen, J.H.; Mekhaldi, S.; Kroon, K.; Wanders, J.; Ravic, M.; Fumoleau, P.; Ducreux, M.; Escudier, B.; Armand, J.P., 2000:
Phase I and pharmacokinetic study of E7070, a new chloro-indolylsulfonamide, given as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

Punt, C.J.A.; Fumoleau, P.; Walle, B.V.D.; Deporte Fety, R.; Bourcier, C.; Faber, M.; Ravic, M.; Wagener, D.J.Th, 2000:
Phase I and pharmacokinetic study of E7070, a novel sulphonamide, given daily X 5 every 3 weeks as a 1-hour intravenous infusion in patients with advanced solid tumors

Forouzesh, B.; Hidalgo, M.; Denis, L.; Schwartz, G.; Hammond, L.; Monroe, P.; Guzman, C.; Supko, J.; Jimeno, J.; Rowinsky, E.K., 2001:
Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer

Bissett, D.; Cassidy, J.; D.B.no, J.S.; Muirhead, F.; Main, M.; Robson, L.; Fraier, D.; Magne, M.L.; Pellizzoni, C.; Porro, M.G.; Spinelli, R.; Speed, W.; Twelves, C., 2004:
Phase I and pharmacokinetic study of MAG-CPT a polymeric derivative of camptothecin

Giles, F.; Tallman, M.; Garcia Manero, G.; Cortes, J.; Thomas, D.; Wierda, W.; Verstovsek, S.; Hamilton, M.; Barrett, E.; Albitar, M.; Kantarjian, H., 2003:
Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

Monnerat, C.; Raymond, E.; Henriksson, R.; Novello, S.; Dutreix, C.; Berthaud, P.; Novelius, E.; Barbier, N.; L.C.evalier, T., 2001:
Phase I and pharmacokinetic study of PKC412, a novel oral Protein Kinase C inhibitor, in combination with gemcitabine and cisplatin in non-small cell lung carcinoma

Denis, L.J.; Rha, S.Y.ung; Ochoa, L.; Hao, D.; Hammond, L.; Simmons, C.; Shannon, P.; Santabarbara, P.; Bentzen, C.; Rowinsky, E.; Tolcher, A., 2001:
Phase I and pharmacokinetic study of SR-45023a , a novel FXR nuclear receptor activator, administered orally on once weekly schedule

Pivot, X.; Chamorey, E.; Guardiola, E.; Renee, N.; Mari, D.; Giroux, B.; Mouri, Z.; Schneider, M.; Milano, G., 2001:
Phase I and pharmacokinetic study of capecitabine and cisplatin in head and neck cancer patients

Kern, W.; Beckert, B.; Lang, N.; Waggershauser, T.; Braess, J.; Schalhorn, A.; Hiddemann, W., 1999:
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer

Asai, G.; Yamamoto, N.; Moriyama, A.; Akiyama, K.; Tsukiyama, S.; Komiya, T.; Uejima, H.; Kurata, T.; Nakagawa, K.; Fukuoka, M., 2001:
Phase I and pharmacokinetic study of irinotecan and paclitaxel in patients with lung cancer

Yamazaki, H.; Hirano, A.; Funakoshi, S.; Kuraishi, Y.; Akiyama, Y.; Sato, T.; Mizunuma, N.; Aiba, K., 1999:
Phase I and pharmacokinetic study of irinotecan given by 24 hours infusion plus oral uracil/tegafur in patients with lung cancer

Strumberg, D.; Schuehly, U.; Moeller, J.G.org; Hedley, D.; Hilger, R.; Stellberg, W.; Richly, H.; Heinig, R.; Kuhlmann, J.; Scheulen, M.E.nst; Seeber, S., 2001:
Phase I and pharmacokinetic study of the Raf kinase inhibitor bay 43-9006 in patients with locally advanced or metastatic cancer

Meyers, P.A.; Gorlick, R.G.; Wexler, L.H.; Nason, S.C.; Cohen, M.B.; Gollerkeri, A., 2003:
Phase I and pharmacokinetic study of the combination of carboplatin and irinotecan in subjects 1-21 years of age with refractory solid tumors

D.B.no, J.S.; Hao, D.; Hammond, L.A.; Tolcher, A.W.; Berg, K.; Bass, A.; Mays, T.; Smith, L.; Drengler, R.; Rowinsky, E.K., 2002:
Phase I and pharmacokinetic study of the epothilone-B analogue BMS-247550 by a continuous weekly schedule

Stephenson, J.; Baker, S.D.; Simmons, C.; Deforges, C.; Proulx, L.; Jolivet, J.; Von Hoff, D.; Rowinsky, E., 1999:
Phase I and pharmacokinetic study of troxacitabine on a daily X 5 day every 4-week schedule

Eskens, F.; Dumez, H.; Verweij, J.; Perschl, A.; Kovar, A.; Brindley, C.; Van Oosterom, A., 2000:
Phase I and pharmacologic study of EMD 121974, an alpha,beta3 and alpha,beta5 integrin inhibitor that pertubs tumor angiogenesis, in patients with solid tumors

Lu, J.; Liebes, L.; Fry, D.; Buckley, M.; Jacobs, A.; Liu, P.; Del Priore, G.; Sorich, J.; Fusco, E.; Hochster, H.; Muggia, F., 2003:
Phase I and pharmacologic study of intraperitoneal topotecan and cisplatin

Schellens, J.H.M.; Kruytzer, M.F.; Vasey, P.A.; Harris, A.L.; Deplanque, G.; Burgess, M.; Dealwis, D.; O'callaghan, M.; Kaye, S.B.; Beijnen, J.H., 2001:
Phase I and pharmacologic study of the P-glycoprotein inhibitor LY335979 and paclitaxel in patients with solid tumors

Schellens, J.H.M.; D.K.erk, G.; Swart, M.; Palmer, P.A.; Bol, C.J.; Van't Veer, L.J.; Tan, H.; Ten Bokkel Huinink, W.W.; Beijnen, J.H., 1999:
Phase I and pharmacologic study with the novel farnesyltransferase inhibitor R115777

Sludden, J.; Boddy, A.V.ncent; Griffin, M.J.; Robson, L.; Todd, R.; Cassidy, J.; Bissett, D.; Main, M.; Brannan, M.D.; Elliott, S.; Verrill, M.; Calvert, H., 2001:
Phase I and pharmacological study of CT-2103, a poly -paclitaxel conjugate

Stevenson, J.P.; Gallagher, M.; Sun, W.; Vaughn, D.J.; Haller, D.G.; Hiller, K.; Tortora, A.; Gupta, E.; Sonnichsen, D.; Skillings, J.; O'dwyer, P.J., 2000:
Phase I clinical and pharmacokinetic study of the taxane analog BMS-184476 administered as a 1-hour IV infusion in combination with carboplatin every 21 days

Stevenson, J.P.; Gallagher, M.; Sun, W.; Algazy, K.; Haller, D.; Thornton, D.; Hiller, K.; O'dwyer, P., 2001:
Phase I clinical and pharmacokinetic trial of cryptophycin-52 administered as an IV infusion on days 1, 4, 8, and 11 every 21 days

Fumoleau, P.; Bennouna, J.; Armand, J.P.; Blanchot, G.; Delgado, F.M.; Marty, M., 2001:
Phase I clinical and pharmacokinetic trial of vinflunine A novel fluorinated vinca alkaloid given on day 1 every 21 days

Liebes, L.; Hochster, H.; Chachoua, A.; Farrell, K.; Rafique, M.; Garbers, S.; Mendoza, S.; Chung, F.L.; Conaway, C.; Malpas, P.; Gehling, A.M.; Crowell, J.; Hecht, S.S., 1999:
Phase I clinical and pharmacokinetics trial of phenethylisothiocyanate in chronic smokers

Bruce, A.W.; Khoury, A.E.; Dicosmo, F.; Ditizio, V.; Sinnadurai, S.; Burrows, L.L., 2001:
Phase I clinical evaluation of a liposomal ciprofloxacin-hydrogel-coated Foley catheter

Thomas, X.; Belhabri, A.; Thiebaut, A.; Chelghoum, Y.; Elhamri, M.; Fiere, D., 2001:
Phase I clinical evaluation of topotecan combined with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia

Carducci, M.A.; Bowling, M.K.; Rogers, T.; Janus, T.J.; Padley, R.J.; Belson, J.B., 1999:
Phase I clinical results of ABT-627, an endothelin receptor antagonist, for refractory adenocarcinomas

D.A.gelo, D.J.; Stone, R.M.; Bruner, R.J.; Caligiuri, M.A.; Heaney, M.L.; Nimer, S.D.; Paquette, R.; Sawyers, C.L.; Lambing, J.L.; Lokker, N.A.; Giese, N.A.; Sinha, V.; Cooper, M.R.; Druker, B.J.; Heinrich, M.C., 2003:
Phase I clinical results with MLN518, a novel FLT3 antagonist Tolerability, pharmacokinetics, and pharmacodynamics

Rossi, S.; Wright, T.; Lin, C.C.ung; Lau, J.Y.; Edalatpour, N.; Fang, J.W., 2001:
Phase I clinical studies of levovirin A second generation ribavirin candidate

Arora, S.; Lau, D.; Gish, R.; Rossi, S.; Lin, C.C.ung; Lau, J.Y.; Fang, J.W., 2002:
Phase I clinical studies of viramidine A liver-targeting prodrug of ribavirin

Novalbos, J.; Galvez Mugica, M.A.; Gallego Sandin, S.; Santos, M.; Gilsanz, F.; Abad Santos, F., 2000:
Phase I clinical trial about the efficacy of a new anesthetic drug, IQB-9302, for ulnar nerve block

Larsen, R.H.; Borch, K.W.; Aas, M.; Fossaa, S.D.; Balteskard, L.; Traasdahl, E.; Hess, S.; Salberg, G.; Henriksen, G.; Schoultz, B.W.; Nilsson, S.; Bruland, O.S., 2002:
Phase I clinical trial exploring the alpha emitting radium-223 against skeletal metastases Blood clearance in patients with breast and prostate cancer

Dees, E.C.; Mckinnon, K.; Myers, M.; Sparks, S.D.; Chwastiak, K.; Collichio, F.; Vandeventer, H.; Carey, L.A.; Brecher, M.E.; Graham, M.; Serody, J.S., 2001:
Phase I clinical trial of HER2 peptide-pulsed autologous dendritic cells in patients with metastatic breast cancer

Szabo, S.K.; Spiro, T.P.; Stevens, S.R.; Horvath, N.; Liu, L.; Cooper, K.D.; Gerson, S.L.; Wood, G.S., 2000:
Phase I clinical trial of O6-benzylguanine and BCNU in cutaneous T cell lymphoma

Herrera, S.; Bonelo, A.; Perlaza, B.L.; Victoria, L.; Velez, J.D.; Badiel, M.; Lenis, A.M.; Soto, L.; Leon, M.; Palacios, R.; Corradin, G.; Arevalo Herrera, M., 2003:
Phase I clinical trial of Plasmodium vivax circumsporozoite protein derived synthetic peptides

Vose, J.M.; Bierman, P.J.; Lynch, J.C.; Bociek, G.R.; Multani, P.S.; Armitage, J.O., 2003:
Phase I clinical trial of Zevalin in patients with B-cell non-Hodgkins lymphoma with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation

Epner, D.E.; Morrow, S.; Varadhachary, G.R.; Hayes, T.G.; Dhingra, H.M.; Berger, D.H., 2001:
Phase I clinical trial of dietary methionine restriction for adults with refractory solid tumors Preliminary results

Cellarier, E.; Durando, X.; Vasson, M.P.ule; Demiden, A.; D'incan, M.; Rolhion, C.; Cabrespine, A.; Mansard, S.; Souteyrand, P.; Madelmont, J.C.aude; Chollet, P., 2003:
Phase I clinical trial of dietary methionine restriction in association with cystemustine treatment Preliminary results

Dietz, J.R.; Kim, J.A.; Dawson, A.; Grundfest, S.F.; Crowe, J.P., 2000:
Phase I clinical trial of mammary ductoscopy in patients with pathologic nipple discharge

Hassen, W.; Sanford, M.A.; Unger, P.; Droller, M.J.; Woo, S.L.C.; Hall, S.J., 2000:
Phase I clinical trial of neoadjuvant adenovirus-mediated HSV-tk gene therapy plus ganciclovir prior to radical prostatectomy

Thanavala, Y.; Scott, A.; Pal, S.; Mahoney, M.; Arntzen, C., 2000:
Phase I clinical trial of orally delivered hepatitis B surface antigen expressed in potato tubers

Chen, S., 2001:
Phase I clinical trial of targeting therapy using 131I-Anti-HBx McAB in patients with hepatocellular carcinoma

Chen, S.L.; Xie, H.; Wu, J.C.; Shi, H.C., 2003:
Phase I clinical trial of targeting therapy using 131I-Hepama-1 McAb in patients with hepatocellular carcinoma

Talpaz, M.; Kantarjian, H.; Freireich, E.; Lopez, V.; Zhang, W.; Cortes Franco, J.; Scheinberg, D.; Rosenblum, M.G., 2003 :
Phase I clinical trial of the anti-CD-33 immunotoxin HuM195/rGel

Repp, R.; Van Ojik, H.H.; Valerius, T.; Groenewegen, G.; Wieland, G.; Oetzel, C.; Stockmeyer, B.; Becker, W.; Eisenhut, M.; Steininger, H.; Deo, Y.M.; Blijham, G.H.; Kalden, J.R.; Van, D.W.nkel, J.G.J.; Gramatzki, M., 2003:
Phase I clinical trial of the bispecific antibody MDX-H210 in combination with Filgrastim for treatment of advanced breast cancer

Heiser, A.; Su, Z.; Dannull, J.; Coleman, D.; Yancey, D.; Maurice, M.; Lallas, C.; Dahm, P.; Niedzwiecki, D.; Gilboa, E.; Vieweg, J.W., 2002:
Phase I clinical trial using dendritic cells transfected with PSA RNA for immunotherapy of prostate cancer patients

Stedman, H.; Wilson, J.M.; Finke, R.; Kleckner, A.L.; Mendell, J., 2000:
Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors

Sauerwein, W.; Hideghety, K.; Moss, R.; Goetz, C.; Pacquis, P.; Rassow, J.; Grochulla, F.; Haselsberger, K.; Wolbers, J.; Turowski, B.; Fankhauser, H.; Stecher Rasmussen, F.; D.V.ies, M.; Gabel, D., 1999:
Phase I clinical trial with BNCT for patients with glioblastoma

Frader, Joel, E., 2001:
Phase I clinical trials The error of therapeutic intent

Meneguz, A.; Massotti, M., 2003:
Phase I clinical trials in Italy Aims and interpretation of requested pre clinical studies

Rodriguez, G.I.; Brooks, D.J.; Burtness, B.A., 1999:
Phase I clinical trials of intravenous 2-deoxycytidine-2-fluoromethylene in patients with advanced solid tumors

Ten Tije, A.J.; Lieverst, J.; Seynaeve, C.; Schornagel, J.; Feragotto, N.; Blanchot, G.; Ter Steeg, J.D.; Laffranchi, B.; Verweij, J.; Schellens, J.H., 2003:
Phase I combination study of oral vinorelbine and oral cyclophosphamide in patients with metastatic breast cancer

Vallabhajosula, S.; Kostakoglu, L.; Goldsmith, S.J.; Kothari, P.; Konishi, T.; Hamacher, K.A.; Ursea, B.; Bander, N.H., 2002:
Phase I dose escalation clinical studies with 177Lu-DOTA-huJ591 A new radiolabeled antibody for the treatment of prostate cancer

Moore, J.D.; Dezube, B.J.; Gill, P.; Zhou, X.J.an; Acosta, E.P.; Sommadossi, J.P.erre, 2000:
Phase I dose escalation pharmacokinetics of O- fumagillol and its metabolites in AIDS patients with Kaposis sarcoma

Rosenzweig, K.E.; Hanley, J.; Mychalczak, B.; Fuks, Z.; Mageras, G.; Yorke, E.; Ling, C.C.; Burman, C.; Ginsberg, R.J.; Kris, M.G.; Leibel, S.A., 2000:
Phase I dose escalation study using the deep inspiration breath hold technique to safely increase dose to 81 Gy in the treatment of inoperable non-small cell lung cancer

Nemunaitis, J.; Cunningham, C.; Uprichard, M.; Kirn, D., 2000:
Phase I dose escalation trial of intravenous infusion of CI-1042 in patients with refractory cancer

Drevs, J.; Mross, K.; Reusch, P.; Peng, B.; Ball, H.; Henry, A.; Laurent, D.; Dugan, M.; Marme, D.; Unger, C., 1999:
Phase I dose escalation, pharmacokinetic study of a novel vascular endothelial growth factor receptor inhibitor, PTK787/ZK 222584

Symonds, R.P.; Chan, S.; Habeshaw, T.; Reed, N.; Mcmahon, L.; Curto, J., 2003:
Phase I dose finding study of capecitabine, cisplatin and radiotherapy in the treatment of locally advanced squamous cervical cancer

Raymond, E.; Vernillet, L.; Boige, V.; Hua, A.; Ducreux, M.; Mekhaldi, S.; Jacques, C.; Gatineau, M.; Mignard, D.; Vergniol, J.C.; Armand, J.P., 1999:
Phase I dose finding study with irinotecan in cancer patients with hepatic dysfunction

Kubo, H.; Gardner, T.A.; Wada, Y.; Koeneman, K.S.; Gotoh, A.; Ling, Y.; Kao, C.; Lim, S.D.g; Amin, M.B.; Yang, H.; Black, M.E.; Matsubara, S.; Nakagawa, M.; Gillenwater, J.Y.; Zhau, H.E.; Chung, L.W., 2003:
Phase I dose-escalation clinical trial of adenoviral osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone refractory prostate cancer

Zhou, X.J.an; Lim, S.G.e; Lai, C.L.ng; Murphy, R.L.; Pow, D.M.; Myers, M.W., 2001:
Phase I dose-escalation pharmacokinetics of L-deoxythymidine in patients with chronic hepatitis B virus infection

Komaki, R.; Swann, S.; Ettinger, D.; Glisson, B.; Sandler, A.; Movsas, B.; Byhardt, R., 2003:
Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer Radiation therapy oncology group RTOG

Sharma, A.K.; Hanna, N.; Nemunaitis, J.; Posner, M.; Rosemurgy, A.; Gupta, S.; Hopkins, U.; Chu, K.; Weichselbaum, R.; Mani, S., 2001:
Phase I dose-escalation study of tumor necrosis factor-alpha gene transfer with radiation therapy for advanced solid tumors

Mel, J.R.; Vieitez, J.M.; Garcia Alfonso, P.; Gonzalez Baron, M.; Alvarez, E.; Jimenez Lacave, A.; Nuevo, J.; Cajal, R.; Bovio, H., 2003:
Phase I dose-escalation study with Raltitrexed combined with UFT in metastatic colorectal cancer

Gordon, L.I.; Mittal, B.B.; Rademaker, A.; Tallman, M.S.; Williams, S.F.; Kaminer, L.; Mehta, J.; Singhal, S.; Patton, D.; Welles, C.; Falco, A.; Fishman, M.; Winter, J.N., 2001:
Phase I dose-escalation trial of total lymphoid irradiation and high-dose chemotherapy with cyclophosphamide, carboplatin and etoposide and autologous peripheral blood stem cell transplantation in patients with relapsed/refractory Hodgkins disease The Northwestern University/Robert H Lurie Comprehensive Cancer Center experience

Zingel, D.; Bolling, C.; Graefe, T.; Radtke, D.; Latz, J.; Blatter, J.; Hanauske, A.R., 2003:
Phase I dose-finding study of the combination of alimta and paclitaxel in patients with solid tumors

Schwartz, G.N.; Bong, D.; Leichman, C.G.; Leichman, L.L., 2000:
Phase I evaluation of anhydrovinblastine in patients with advanced malignancies

Willoughby, R.; Watson, D.; Welliver, R.; Cox, S.R.; Wathen, L.; Paxton, L.; Freimuth, W., 1999:
Phase I evaluation of delavirdine in HIV-1-infected pediatric patients

Pithavala, Y.K.; Hsyu, P.H.; Gersten, M.; Crampton, S.; Penning, C.A.; Daniels, R.G.; Zhang, K.; Paradiso, L.; Kerr, B.M., 1999:
Phase I evaluation of the safety and pharmacokinetics of intranasal AG7088, a novel investigational 3-C protease inhibitor

Wiseman, G.A.; Dispenzieri, A.; Anderson, P.M., 2001:
Phase I high dose 153Samarium ethylenediaminetetramethylenephosphonate and melphalan therapy of multiple myeloma with peripheral blood stem cell support

Lo, N.; Ayers, S.; Catell, E.; Koetz, B.; Singh, N.; Alexander, G.; Lower, F.; Rea, D.W., 2004:
Phase I intrapatient dose escalation study of weekly epirubicin and docetaxel as first line chemotherapy in metastatic breast cancer

Ristamaki, R.; Glimelius, B.; Linne, T.; Boussard, B.; Oulid Aissa, D.; Pyrhonen, S., 1999:
Phase I of CPT-11 combined with 5-FU/folinic acid

Blum, M.R.; Chittick, G.E.; Wang, L.H.; Fang, L.; Szczech, G.M.; Rousseau, F., 2000:
Phase I pharmacokinetic and safety evaluation of clevudine , a new agent under development for the treatment of hepatitis B virus infection

Delbaldo, C.; Pierga, J.Y.es; Dieras, V.; Vedovato, J.C.aude; Mueser, M.; Bonnet, M.; Nolting, A.; Kovar, A.; Faivre, S.; Kisker, O.; Raymond, E., 2003:
Phase I pharmacokinetic evaluation of the interaction between cetuximab and irinotecan in patients with EGFR positive advanced solid tumors

Sharma, R.A.; Ireson, C.R.; Mclelland, H.R.; Hill, K.A.; Euden, S.A.; Leuratti, C.; Williams, M.L.; Plummer, S.M.; Manson, M.M.; Gescher, A.; Steward, W.P., 2001:
Phase I pharmacokinetic study of Curcuma extracts in patients with colorectal cancer including measurement of chemotherapeutic and chemopreventive indices

Bos, A.M.E.; Seegers, M.; Roelvink, M.W.J.; Wanders, J.; Hanauske, A.R.; Bortini, S.; Capriati, A.; Uges, D.R.A.; D.V.ies, E.G.E.; Vermorken, J.B., 1999:
Phase I pharmacokinetic study of MEN-10755 in solid tumors

Remick, S.C.; Dowlati, A.; Robertson, K.; Spiro, T.; Connell, C.; Levitan, N., 2000:
Phase I pharmacokinetic study of single dose intravenous combretastatin A4 prodrug in patients with advanced cancer

Korst, A.E.C.; Dyck, J.; Schrijvers, D.; Lardon, F.; Vermorken, J.B., 2000:
Phase I pharmacokinetic study of the combination of gemcitabine, vinorelbine and cisplatin

Dunphy, F.R.; Cantrell, C.; Dunleavy, T.; Visconti, J.; Richart, J.; Pincus, S.; Petruska, P.; Duncan, B.; Schaaf, L., 2000:
Phase I pharmacokinetics Doxil and CPT-11 in solid tumors

Visich, J.E.; Reynolds, T.C.; Byrnes Blake, K.; Zuckerman, L.A.; Dodds, M.G.; Vicini, P.; Rogge, M., 2003:
Phase I pharmacokinetics of a single dose of recombinant factor XIII administered to healthy volunteers

Gill, S.C.; Moon Mcdermott, L.; Hunt, T.L.; Deresinski, S.; Blaschke, T.; Sandhaus, R.A., 1999:
Phase I pharmacokinetics of liposomal amikacin in human subjects Dose dependence and urinary clearance

Liebes, L.; Hochster, H.; Chachoua, A.; Farrell, K.; Garbers, S.; Mendoza, S.; Chung, F.L.ng; Conaway, C.; Carmella, S.; Murphy, S.E.; Hecht, S.; Crowell, J., 2000:
Phase I pharmacokinetics of single dose administration of phyethy isothiocyanate and effects on nicotine metabolism

Aghajanian, C.; Sabbatini, P.; Hensley, M.; Spriggs, D., 1999:
Phase I pharmacology study of carboplatin and weekly paclitaxel in platinum-sensitive ovarian cancer patients with recurrent disease

Chong, G.; Lee, F.; Hopkins, W.; Mountain, A.; Potasz, N.; Murphy, R.; Chappell, B.; Schleyer, P.; Papenfus, T.; O'keefe, G.J.; Cebon, P.U.J.; Mitchell, P.; Poon, A.; Burgess, A.W.; Hoffman, E.; Old, L.J.; Scott, A.M., 2003:
Phase I radioimmunotherapy trial of 131I-huA33 in patients with advanced colorectal carcinoma

Trabulsi, E.J.; Yao, D.; Joyce, M.A.; Milowksy, M.; Kostakoglu, L.; Vallabhajosula, S.; Nanus, D.; Goldsmith, S.; Bander, N.H., 2003:
Phase I radioimmunotherapy trials of monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen radiolabeled with 90yttrium or 177lutetium in advanced prostate cancer

Chakravarti, A.; Seiferheld, W.; Robbins, I.; Guha, A.; Sperduto, P.; Choucair, A.; Brachman, D.; Mehta, M., 2003:
Phase I results from RTOG BR-0211, a Phase I/II study of an oral epidermal growth factor receptor tyrosine kinase inhibitor , ZD 1839 , with radiation therapy in glioblastoma multiforme

Gordon, L.I.; Moore, J.O.; Cheson, B.D.; Czuczman, M.; Younes, A.; Leonard, J.P.; Forero Torres, A.; Sweetenham, J.W.; Chieffo, N.; Thall, A.; Leigh, B.R., 2003:
Phase I results from a multicenter trial of galiximab in combination with Rituximab for the treatment of follicular lymphoma

Thompson, H.S.; Davies, M.L.; Holding, F.P.; Fallon, R.E.; Mann, A.E.; O'Neill, T.; Roberts, J.S., 1999:
Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts

Esteva, F.J.; Theriault, R.; Rivera, E.; Chang, H.Y.n; Cristofanilli, M.; Buzdar, A.; Booser, D.; Pusztai, L.; Rosales, M.; Hortobagyi, G.N., 2001:
Phase I safety and dose-finding study of human mammary epithelial cell-derived mammastatin for metastatic breast cancer

Kondziolka, D.; Wechsler, L.; Thulborn, K.; Meltzer, C.; Goldstein, S.; Jannetta, P.; Slagel, C.; Elder, E., 1999:
Phase I safety and effectiveness trial of the cerebral transplantation of LBS-neurons in patients with substantial fixed motor deficit following cerebral infarction

Halperin, S.; Mcneil, S.; Smith, B.; Langley, J.; Allard, F.; Jones, T.; Burt, D.; White, G.; Mallett, C.; Lowell, G.; Fries, L., 2002:
Phase I safety and immunogenicity of FluINsure, proteosome-trivalent influenza vaccine, given nasally to adults

Malfertheiner, P.; Schultze, V.; Giudice, G.D.; Rosenkranz, B.; Kaufmann, S.H.E.; Winau, F.; Ulrichs, T.; Theophil, E.; Jue, C.P.; Novicki, D.; Norelli, F.; Contorni, M.; Berti, D.; Lin, J.S.ing; Schwenke, C.; Goldman, M.; Tornese, D.; Ganju, J.; Pal, 2002:
Phase I safety and immunogenicity of a three-component H pylori vaccine

Peeters, P.; Hohenboken, M.; Lebacq, E., 1999:
Phase I safety evaluation of an undecavalent pneumococcal conjugated vaccine in young adults

Van Echo, D.A.; Kennedy, A.S.; Suntharalingam, M., 2002:
Phase I studies of Xeloda plus chemotherapy and radiation in head/neck or gastrointestinal cancers

Lorusso, P.M., 2003:
Phase I studies of ZD1839 in patients with common solid tumors

Meredith, R.F.; Alvarez, R.; Partridge, E.; Khazaeli, M.B.; Austin, J.M.x; Kilgore, L.; Grizzle, W.; Schlom, J.; Lobuglio, A., 2001:
Phase I studies of combined modality intraperitoneal therapy of ovarian cancer

Scheibenbogen, C.; Schadendorf, D.; Foerster, M.H.; Servetopoulou, F.; Schmittel, A.; Siehl, J.; Nagorsen, D.; Hofmann, U.; Thiel, E.; Keilholz, U., 2000:
Phase I studies of vaccination with tyrosinase peptides and various adjuvants in high-risk cutaneous and ocular melanoma patients

Reiqner, B.; Jordan, P.; Pannier, A.; Glaspy, J., 2003:
Phase I studies with CERA , an innovative erythropoietic agent

Schrijvers, D.; Vermorken, J.B., 2002:
Phase I studies with bendamustine: an update

Kuebler, H.; Brill, T.; V.R.ndenborgh, H.; Fend, F.; Pohla, H.; Schendel, D.; Breul, J.; Hartung, R.; Paul, R.; Gaensbacher, B., 2003:
Phase I study Cancer gene therapy of hormone refractory prostate cancer patients with a retrovirally transfected IL2-IFNgamma-secreting allogeneic tumorvaccine

Gonzalez, E.; Sanchez Rovira, P.; Jaen, A.; Porras, I.; Medina, B.; Duenas, R.; Mohedano, N.; Fernandez, M.; Lozano, A., 1999:
Phase I study concomitant gemcitabine with radiotherapy in stage III NSCLC

Burges, A.; Wimberger, P.; Gorbounova, V.A.; Sommer, H.; Schmalfeldt, B.; Pfisterer, J.; Stroehlein, M.; Lichinitser, M.R.; Makhson, A.N.; Kimmig, R., 2003:
Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab

Mcewan, A.J.; Schmidt, R.P.; Morin, C.A.; Logus, J.W.; Chmielowiec, C.J., 2000:
Phase I study of 111In octreotide therapy in patients with neuroendocrine tumors

Middleton, M.R.; Ranson, M.; Bowen, R.; Mcelhinney, R.S.; Mcmurry, T.B.H.; Thatcher, N.; Newell, D.R.; Margison, G.P., 2000:
Phase I study of 4-bromothenylguanine and temozolomide Preliminary results and O6-alkyl-guanine-DNA alkyltransferase depletion

Verschraegen, C.F.; Vincent, M.; Abbruzzese, J.L.; Siegler, D.; Kavanagh, J.J.; Loyer, E.; Kudelka, A.P.; Rubin, E., 2000:
Phase I study of 9-nitro-20 -camptothecin in combination with cisplatin for patients with advanced malignancies

Gilbert, B.E.; Verschraegen, C.F.; Huaringa, A.A.; Newman, R.A.; Knight, V., 2002:
Phase I study of 9-nitrocamptothecin liposome aerosol for the treatment of primary and metastatic cancer to the lungs Effect of dose escalation on bronchoalveolar lavage and plasma drug levels

Buck, R.H.; Robert, F.; Meredith, R.F.; Grizzle, W.E.; Khazaeli, M.B.; Lobuglio, A.F., 2000:
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer

Giles, F.; Cortes, J.; Thomas, D.; Verstovsek, S.; Garcia Manero, G.; Faderl, S.; Ferrajoli, A.; Hagey, A.; Gordon, G.; Kantarjian, H., 2003:
Phase I study of ABT-751, a novel tubulin-binding agent, in patients with refractory hematological malignancies

Levine, A.; Fayad, L.; Modiano, M.; Camboni, G.; Cabinallas, F., 2003:
Phase I study of BBR-2778 in BSHAP for relapsed aggressive non-Hodgkins lymphoma

Sessa, C.; Highley, M.; Pagani, O.; Plummer, R.; D.J.ng, J.; Smith, K.; Bogaerts, J.; Renard, J.; Winograd, B.; Gallant, G., 1999:
Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies

Alexandre, J.; Raymond, E.; Depenbrock, H.; Mekhaldi, S.; Angevin, E.; Paillet, C.; Hanauske, A.; L.C.evalier, T.; Escudier, B.; Frisch, J.; Feussner, A.; Armand, J.P., 2000:
Phase I study of CCl-779, a novel rapamycin analog Preliminary results

Braud, A.; Goncalves, A.; Genre, D.; Gravis, G.; Viret, F.; Camerlo, J.; Cappiello, M.; Blaise, D.; Maraninchi, D.; Viens, P., 2001:
Phase I study of Caelyx and Carboplatin in patients with advanced or metastatic solid tumors

Rivera, E.; Baysinger, L.; Asmar, L.; Valero, V.; Hortobagyi, G.N., 1999:
Phase I study of Gemcitabine and Doxil combination chemotherapy in patients with metastatic breast cancer Preliminary results

Maki, R.G.; Lewis, J.J.; Janetzki, S.; Klimstra, D.; Desantis, D.; Hirst, C.; Houghton, A.N.; Srivastava, P.K.; Brennan, M.F., 2003:
Phase I study of HSPPC-96 vaccine in patients with completely resected pancreatic adenocarcinoma

Sugiura, T.; Hida, T.; Yoshida, K.; Hyodo, I.; Sumiyoshi, Y.; Takashima, S.; Horikoshi, N.; Aiba, K.; Kuwabara, T.; Ogawa, M., 2002:
Phase I study of KW-170, a novel pyrazoloacridone compound against solid tumors

Alexandre, J.; Chieze, S.; Raymond, E.; Brain, E.; Kaci, M.O.ld; Smith, S.; Lagree, S.; Vanderbilt, K.; Cvitkovic, E.; Kahatt, C., 2001:
Phase I study of MGI 114 exploring 3 different iv schedules as a 5 minute infusion in advanced solid tumors Final results

Raymond, E.; Alexandre, J.; Brain, E.; Faivre, S.; Kaci, M.O.ld; Vignot, S.; Smith, S.; Lagree, S.; Vanderbilt, K.; Misset, J.L., 2001:
Phase I study of MGI 114 given as either D1, D8 q3 weeks or D1, D15 q4 weeks schedule as a 30 minute infusion in advanced solid tumors Preliminary results

Prados, M.; Chang, S.; Burton, E.; Parney, I.; Kapadia, A.; Rabbitt, J.; Page, M.; Federoff, A.; Kelley, S.; Fyfe, G., 2003:
Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma

Hutson, T.E.; Mekhail, T.; Weiss, P.; Roman, S.; Dreicer, R.; Peereboom, D.; Olencki, T.; Kelly, G.; Ganapathi, R.; Bukowski, R.M., 2002:
Phase I study of PhenoxodiolTM given by constant intravenous infusion in patients with solid neoplasms refractory to standard therapy

Awada, A.; Bleiberg, H.; Gil, T.; Lehmann, F.; Marien, K.; Gerard, B.; Lucas, C.; Giroux, B.; Piccart, M., 1999:
Phase I study of S16020 a topoisomerase II inhibitor given q 3 w as a 3-h infusion

Dizon, D.S.; Maluf, F.; Aghajanian, C.; Daud, A.; Sabbatini, P.; Soignet, S.; Krug, L.; Pezzulli, S.; Spriggs, D.R.; Beale, P., 2001:
Phase I study of ZD0473 and liposomal doxorubicin in advanced refractory solid tumor malignancies

Cortes, J.; O'brien, S.; Ferrajoli, A.; Daley, G.Q.; Pate, O.; Verstovsek, S.; Faderl, S.; Zhu, Y.; Sugrue, M.; Statkevich, P.; Talpaz, M.; Kantarjian, H., 2003:
Phase I study of a imatinib and lonafarnib in patients with chronic myeloid leukemia refractory to imatinib mesylate

Cortes, J.; Garcia Manero, G.; O'brien, S.; Hernandez, I.; Rackoff, W.; Faderl, S.; Thomas, D.; Talpaz, M.; Kantarjian, H., 2003:
Phase I study of a imatinib and tipifarnib in patients with chronic myeloid leukemia in chronic phase refractory to imatinib

Halperin, S.A.; Smith, B.; Clarke, K.; Mabrouk, T.; Germain, M., 1999:
Phase I study of a nasally delivered trivalent influenza vaccine incorporating inactivated influenza antigens with supra-molecular biovector delivery technology

Mcneel, D.G.; Knutson, K.L.; Schiffman, K.; Davis, D.; Caron, D., 2002:
Phase I study of a peptide-based vaccine targeting HER-2/neu in patients with advanced stage prostate cancer

Arai, S.; Kindy, K.; Swearingen, M.; Meagher, R.C.; Friend, P.; Maki, G.; Martinson, J.; Myint, H.; Klingemann, H.G.org, 2003:
Phase I study of adoptive immunotherapy using the cytotoxic natural killer cell line, NK-92, for treatment of advanced renal cell carcinoma and malignant melanoma

Muggia, F.; Haigentz, M.; Hochster, H.; Macapinlac, M.; Mirchandani, D.; Sorich, J.; Lee, J.; Sewak, S.; Kim, M.; Hamilton, A., 2001:
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination

Tong, M.J.; Langenberg, A.; Narayanan, G.; Lin, J.S.ing; Chien, D.Y.; Koff, R.S.; Kugelmas, M.; Rustgi, V.K.; Hsu, H.H.; Wright, T.L., 2001:
Phase I study of an adjuvanted immunotherapy in combination with lamivudine for the treatment of chronic hepatitis B in adults

Ten Tije, A.J.n; Lieverst, J.; Seynaeve, C.; Schornagel, J.H.; Brandely, M.; Laffranchi, B.; Blanchot, G.; Ter Steeg, J.; Verweij, J.; Schellens, J.H.M., 2003:
Phase I study of an all-oral combination of vinorelbine and cyclophosphamide as second line treatment in patients with metastatic breast cancer

Gustin, D.M.tias; Winegarden, J.; Haraf, D.; Stenson, K.; Dekker, A.; Stadler, W.; Vokes, E., 2003:
Phase I study of bevacizumab, fluorouracil, hydroxyurea and radiotherapy for patients with poor prognosis head and neck cancer

Cohen, E.E.W.; Hoffman, P.C.; Masters, G.T.; Haraf, D.J.; Mauer, A.M.; Rudin, C.M.; Watson, S.M.; Szeto, L.; Booda, M.K.; Vokes, E.E., 2000:
Phase I study of carboplatin and vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer

Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Duck, L.; Bessa, E.; Mueser, M.; Amellal, N., 2003:
Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Brenner, M.K.; Heslop, H.; Krance, R.; Horowitz, M.; Strother, D.; Nuchtern, J.; Grilley, B.; Martingano, E.; Cooper, K., 2000:
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector

Kiura, K.; Ueoka, H.; Fujimoto, N.; Takata, I.; Nagata, T.; Kunisada, K.; Katayama, H.; Mimoto, J.; Nogami, N.; Hiraki, A.; Harada, M., 2000:
Phase I study of cisplatin, docetaxel and irinotecan for advanced non-small cell lung cancer

Cross, A.S.; Drabick, J.; Opal, S.M.; Warren, H.S.; Bhattacharjee, A.K., 2001:
Phase I study of detoxified Escherichia coli J5 lipopolysaccharide /group B meningococcal outer membrane complex in human subjects

Cross, A.S.; Opal, S.M.; Palardy, J.E.; Drabick, J.J.; Warren, H.S.aw; Huber, C.; Cook, P.; Bhattacharjee, A.K., 2003:
Phase I study of detoxified Escherichia coli J5 lipopolysaccharide /group B meningococcal outer membrane protein complex vaccine in human subjects

Ackland, S.; Rischin, D.; Beith, J.; Gupta, S.; Wyatt, S.; Davison, J.; Johnson, C.; Teriana, N., 1999:
Phase I study of docetaxel epirubicin and cyclophosphamide in patients with advanced cancer

Bildat, S.; Gatzemeier, U.; Reck, M.; Harstrick, A.; Eberhardt, W.; Achterrath, W.; Krauss, C.; Wilke, H.J., 1999:
Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy in patients with metastatic non-small cell lung cancer

Rivera, E.; Ricks, R.; Valero, V.; Cristofanilli, M.; Rosales, M.; Hortobagyi, G., 2000:
Phase I study of eniluracil plus oral 5-fluorouracil in combination with docetaxel for the treatment of patients with metastasis breast cancer Preliminary results

Connolly, N.; Harrop, R.; Mcneill, H.; Garner, C.; Fenemore, J.; Saunders, M.; Valle, J.; Kingsman, S.; Carroll, M.; Hawkins, R., 2003:
Phase I study of escalating doses of TroVax in patients with advanced colorectal cancer

Bhalla, K.; Landry, J.; Harris, W.B.; Daneker, G.; Myers, M.; Staley, C., 1999:
Phase I study of gemcitabine, cisplatinum, 5-fluorouracil, and leucovorin with G-CSF support in pancreatic and other gastrointestinal cancers A preliminary report

Cagnoni, P.J.; Cook, B.; Johnson, T.K.; Cole, W.C.; Quaife, R.; Matthes, S.M.; Shpall, E.J.; Bearman, S.I.; Nieto, Y.; Ceriani, R.L.; Jones, P.B., 2000:
Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous hematopoietic stem cell support in patients with refractory metastatic breast cancer

Gojo, I.; Gore, S.D.; Jiemjit, A.; Greer, J.; Tidwell, M.L.; Sparreboom, A.; Figg, W.D.; Heyman, M.R.; Rollins, S.; Trepel, J.; Sausville, E.A.; Karp, J.E., 2003:
Phase I study of histone deacetylase inhibitor MS-275 in adults with refractory or relapsed hematologic malignancies

Nogami, T.; Negoro, S.; Masuda, N.; Kudoh, S.; Nakagawa, K.; Fukuoka, M., 2001:
Phase I study of intermittent topotecan in non small cell lung cancer

Hood, D.D.; Eisenach, J.C.; Curry, R., 1999:
Phase I study of intrathecal adenosine in volunteers

Goal, R.; Maroun, J.; Cripps, C.; Jonker, D.; Chiritescu, G.; Dahrouge, S.; Douglas, L., 2003:
Phase I study of irinotecan , raltitrexed , and 5-fluorouracil in the treatment of metastatic colorectal cancer refractory to thymidylate synthase inhibitors

Komatsu, Y.; Takei, M.; Kato, T.; Miyagishima, T.; Kunieda, Y.; Tateyama, M.; Wakahama, O.; Takeda, H.; Kato, M.; Sugiyama, T.; Asaka, M.; Sakata, Y., 2002:
Phase I study of irinotecan combined with S-1 in patients with advanced gastric cancer

Seibel, N.L.; Perentesis, J.P.; Stine, K.C.; Trueworthy, R.C.; Weinthal, J.; Weitman, S.; Cox, M.A.; Baum, C.M.; Needle, M.N., 1999:
Phase I study of leridistim in pediatric patients treated with ICE chemotherapy

Thomas, A.; Shields, F.; Wells Jordan, P.; Lloyd, D.; Hubbard, A.; Steward, W.P.; O'byrne, K.J., 1999:
Phase I study of liposomal daunorubicin in the treatment of metastatic breast cancer

Roelvink, M.; Aamdal, S.; Dombernowsky, P.; Wanders, J.; Peters, S.; Bortini, S.; Crea, A.; Animati, A.; Hanauske, A.R., 1999:
Phase I study of men-10755 in patients with a solid tumor as a short iv infusion given once every 3 weeks

Schiaffi, J.; Del Carmen Bover, L.; Scarano, D.; Bravo, A.I.; Bagnati, A.; Machiavelli, L.; Urrutia, A.; Yomha, R.; Mordoh, J., 2000:
Phase I study of monoclonal antibody FC-215 and chemotherapy with fluoruracil-epirubicin-cyclophosphamide in advanced breast cancer patients

Schilder, R.J.; Gallo, I.M.; Johnson, S.W.; Kindsfather, S.K.; Chernoff, M.; Millenson, M.M.; Bookman, M.A.; Adams, A.; Cicotto, S.; Boente, M.; Rosenblum, N.; Hogan, W.M.; Rogers, B.; Padavic Shaller, K.; Yeung, C.; Kilpatrick, D.; Hiller, K.; Rogatko, A.; Weiner, L.M.; Ozols, R.F., 1999:
Phase I study of multiple cycles of high-dose topotecan, carboplatin, and paclitaxel with peripheral blood stem cell support

D.P.lma, M.; Brain, E.C.; Etoussami, A.; Gerard, B.; Giroux, B.; Chouaki, N.; Turpin, F.; Misset, J.L., 1999:
Phase I study of olivacine in a weekly schedule Preliminary results

Malkowicz, S.B.uce; Broderick, G.A.; Zoltick, B.; Marks, S.H.F.; Treat, J.; Tomaszewski, J.; Propert, K.; Wein, A.J.; Kennedy, A.R., 1999:
Phase I study of oral Bowman-Birk inhibitor concentrate , a soy protein, on patients with lower urinary tract symptoms

Shoskes, D.A.; Thomas, M.; Pobgee, R.; Fromkin, B.; Copley, J.B., 2003:
Phase I study of oral bioflavonoids in cadaveric renal transplant recipients: effects on delayed graft function and calcineurin inhibitor toxicities

Shoskes, D.; Thomas, M.; Pobgee, R.; Tapolyai, M., 2002:
Phase I study of oral bioflavonoids in renal transplant recipients Tolerability and effects on renal function and calcineurin toxicity

Olek, M.J.; Smith, D.R.; Cook, S.L.; Khoury, S.J.; Weiner, H.L., 2001:
Phase I study of oral recombinant ovine interferon-tau in relapsing-remitting multiple sclerosis

Garcia Manero, G.; Canalli, A.A.; Wierda, W.; Cortes, J.; O'brien, S.; Cupo, A.; Secrist, J.P.ul; Davis, J.; Faderl, S.; Giles, F.; Chiao, J.H.; Richon, V.; Issa, J.P.erre; Kantarjian, H., 2003:
Phase I study of oral suberoylanilide hydroxamic acid in patients with advanced leukemias or myelodysplastic syndromes

Bulgaru, A.M.; Goel, S.; Zamboni, W.; Hochster, H.; Wadler, S.; Lagattuta, T.F.; Freda, T.; Brisar, C.; Egorin, M.J.; Mani, S., 2003:
Phase I study of oxaliplatin in combination with 5-fluorouracil and gemcitabine in patients with solid tumors

Mavroudis, D.; Kouroussis, C.; Kakolyris, S.; Agelaki, S.; Kalbakis, K.; Androulakis, N.; Souglakos, J.; Samonis, G.; Georgoulias, V., 2002:
Phase I study of paclitaxel and pegylated liposomal doxorubicin administered every 2 weeks in patients with advanced solid tumors

Dittrich, C.; Petruzelka, L.; Vodvarka, P.; Gneist, M.; Janku, F.; Kysela, T.; Downie, L.; Klima, M.; Krejcy, K., 2002:
Phase I study of pemetrexed and cyclophosphamide in patients with locally advanced or metastatic breast cancer

Valkema, R.; De Jong, M.; Bakker, W.H.; Breeman, W.A.p.; Kooij, P.P.m.; Lugtenburg, P.J.; De Jong, F.H.; Christiansen, A.; Kam, B.L.r.; De Herder, W.W.; Stridsberg, M.; Lindemans, J.; Ensing, G.; Krenning, E.P., 2002:
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

Quinn, H.; Mathur, P.; Glover, C.; Mccall, J.; Allen Mersh, T.G., 1999:
Phase I study of percutaneous hepatic cryotherapy

Kruit, W.H.J.; Schuler, J.; Portielje, J.E.A.; Beck, J.; Lamers, C.; Huber, C.; Gratama, J.W.; D.B.er Dennert, M.; Rakhit, A.; Aulitzky, W.E.; Bolhuis, R.L.H.; Stoter, G., 1999:
Phase I study of recombinant interleukin-12 subcutaneously in patients with advanced renal cell carcinoma

Rischin, D.; Prince, M.; Quinn, M.; Allen, D.; Planner, R.; Davison, J.; Gates, P., 1999:
Phase I study of repetitive high-dose topotecan carboplatin and paclitaxel in previously untreated ovarian cancer

Freytag, S.O.; Kim, J.H.; Khil, M.; Stricker, H.; Peabody, J.; Nafziger, D.; Deperalta Venturina, M.; Aguilar Cordova, E., 2002:
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for local recurrence of prostate cancer

Freytag, S.O.; Kim, J.H.; Khil, M.; Nafziger, D.; Menon, M.; Peabody, J.; Stricker, H.; Deperalta Venturina, M.; Pegg, J.; Aguilar Cordova, E., 2000:
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for local recurrence of prostate cancer after definitive radiation therapy

Sewell, L.; Tami, J.; Geary, R.; Mant, T.; Dorr, A.; Glover, J., 2001:
Phase I study of sc and iv ISIS 104838 , a second generation antisense oligonucleotide

Cortes, J.; O'brien, S.; Verstovsek, S.; Thomas, D.; Giles, F.; Garcia Manero, G.; Murgo, A.; Newman, R.; Rios, M.B.th; Talpaz, M.; Kantarjian, H., 2003:
Phase I study of subcutaneous homoharringtonine for patients with chronic myelogenous leukemia

Newlands, E.S.; Foster, T.; Zaknoen, S., 2003:
Phase I study of temozolamide combined with procarbazine in patients with gliomas

Van, D.K.rkhove, M.P.; D.F.orio, E.; Scuderi, V.; Mancini, A.; Belli, A.; Bracco, A.; Dauri, M.; Tisone, G.; D.N.cuolo, G.; Amoroso, P.; Spadari, A.; Lombardi, G.; Hoekstra, R.; Calise, F.; Chamuleau, R.A.F.M., 2002:
Phase I study of the AMC-bioartificial liver in patients with acute liver failure

D.B.no, J.S.; Baker, S.D.; Stephenson, J.Jr.; Simmons, C.; Goetz, A.; Prouix, L.; Jolivet, J.; Hidalgo, M.; Von Hoff, D.D.; Rowinsky, E.K., 2001:
Phase I study of the L-stereoisomer nucleoside analogue troxacitabine

Cobbold, M.; Khan, N.; Tauro, S.; Mcdonald, D.; Ollavaria, E.; Chakraverty, R.; Goldman, J.; Mahendra, P.; Craddock, C.; Moss, P., 2003:
Phase I study of the adoptive transfer of tetramer selected cytomegalovirus-specific cytotoxic T cells after allogeneic stem cell transplantation

Mccrystal, M.R.; Evans, B.D.; Harvey, V.J.; Thompson, P.I.; Porter, D.J.; Baguley, B.C., 1999:
Phase I study of the cytotoxic agent N- ethylacridine-4-carboxamide

Mavroudis, D.; Kourousis, C.; Kakolyris, S.; Agelaki, S.; Kalbakis, K.; Androulakis, N.; Souglakos, J.; Vardakis, N.; Samonis, G.; Georgoulias, V., 2000:
Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report

Mcmullen, K.P.; Deguzman, A.F.; Shaw, E.G.; Tatter, S.B.; Danak, S.; Yates, C.; Rosenblum, M.L.; Mikkelson, T.; Olivi, A.; Grossman, S., 2000:
Phase I study of the gliasite radiotherapy system for brachytherapy of brain tumor resection cavities

Kuritani, J.; Abdelhameed, M.; Boyeson, M.; Dixon, R.M.; Pfefferkorn, C.; Yonezawa, J.; Shindo, T.; Minami, Y.; Buzdar, A.U., 2001:
Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women

Orlowski, R.Z.; Voorhees, P.M.; Garcia, R.A.; Hall, M.D.; Lehman, M.J.; Johri, A.; Humes, E.; Adams, J.; Esseltine, D.L.; Gabriel, D.A.; Shea, T.C.; Van Deventer, H.W.; Mi, 2003:
Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies

Gordon, A.N.; Doherty, M.; Hancock, K.C.; Messing, M.; Matthews, C.M.; Teneriello, M.; Patton, T.; Stringer, C.A., 1999:
Phase I study of topotecan with carboplatin alternating with paclitaxel via 3 hour infusion with carboplatin in treatment of newly diagnosed ovarian cancer

Maroun, J.A.; Jonker, D.; Seymour, L.; Goel, R.; Kocha, W.; Fisher, B., 2001:
Phase I study of triple drug combination of CPT-11 , oxaliplatin and tomudex in previously untreated metastatic colorectal cancer National Cancer Institute of Canada Clinical Trials Group , IND135

Campone, M.; Fumoleau, P.; Tekiela, A.; Koralewski, P.; Bonneterre, J.; Blanchot, G.; Longerey, B.; Favier, P., 2003:
Phase I study of vinorelbine alternating iv and oral in combination with docetaxel as 1st line chemotherapy of metastatic breast cancer

Nole, F.; Catania, C.; Mandala, M.; Zampino, M.G.; Munzone, E.; Ferretti, G.; Curigliano, G.; Marrocco, E.; Lambiase, A.; Goldhirsch, A., 2000:
Phase I study of vinorelbine and capecitabine in advanced breast cancer

Villalona Calero, M.A.; Shapiro, C.; Otterson, G.A.; Hauger, M.; Kraut, E.; Clinton, S.; Shah, M.; Stanek, M.; Monk, J.P., 2000:
Phase I study of weekly docetaxel in combination with capecitabine in patients with solid malignancies

Berenson, J.; Swift, R.; Borg, T.; Knight, R., 2000:
Phase I study of zoledronate administered as a 30-60 second intravenous infusion in cancer patients

Lipton, A.; Berenson, J.; Rosen, L.; Hu, G.; Knight, R., 2000:
Phase I study of zoledronate in cancer patients with lytic bone disease

Link, B.K.; Ballas, Z.K.; Weisdorf, D.; Albert, G.; Shannon, M.; Rasmussen, W.; Venhaus, R.R.; Eaton, C.; Krieg, A.; Weiner, G.J., 2001:
Phase I study to assess safety and activity of oligodeoxynucleotide CpG 7909 in patients with previously treated non-Hodgkins lymphoma

Lesimple, T.; Hassel, M.B.n; Gedouin, D.; Garsin, B.; Simon, H.; Malhaire, J.P.; Leberre Herresbach, N.; Benhammouda, A.; Guegan, Y., 2001:
Phase I study with continuous infusion dose escalated 5 day schedule topotecan and radiation therapy for patients with previously untreated glioblastoma

Hehr, T.; Grabenbauer, G.; Zimmermann, F.; Hoffmann, W.; Bamberg, M.; Budach, W., 2003:
Phase I study with topotecan and simultaneous radiation in patients with non small cell lung cancer stage III B

Briasoulis, E.; Tzamakou, E.; Rammou, D.; Karavasilis, V.; Haidou, K.; Garanatsi, V.; Pavlidis, N., 1999:
Phase I trial and interaction pharmacokinetics of PEG-liposomal doxorubicin and weekly taxol

Brian, E.; D.P.lma, M.; Etassami, A.; Quabdesselam, R.; Gerard, B.; Chouaki, N.; Lucas, C.; Brillanceau, M.H.; Giroux, B.; Turpin, F.; Misset, J.L., 1999:
Phase I trial and pharmacokinetic study of S16020 according to a weekly and every 2 week schedule in cancer patients

Winter, J.N.; Inwards, D.; Erwin, W.; Wiseman, G.; Rademaker, A.; Patton, D.; Williams, S.; Tallman, M.; Mehta, J.; Singhal, S.; Micallef, I.; Spies, S.; Multani, P.; Zimmer, M.; White, C.; Gordon, L.I., 2001:
Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL

Petak, I.; Tillman, D.M.; Stewart, C.; Turner, P.K.; Vernes, R.; Douglas, L.; Mihalik, R.; Sorrentino, B.P.; Schwartzberg, L.; Houghton, J.A., 2001:
Phase I trial of 5-fluorouracil , leucovorin and interferon-gamma based upon modulation of Fas signaling

Yao, D.; Sandhu, J.S.; Trabulsi, E.J.; Liu, H.; Nanus, D.; Joyce, M.; Navarro, V.; Kim, S.; Xia, J.; Kostakoglu, L.; Smith Jones, P.; Vallabhajosula, S.; Goldsmith, S.; Bander, N.H., 2002:
Phase I trial of 90yttrium-dota-huJ591 , a radioisotope labeled humanized monoclonal antibody to the extracellular domain of prostate specific membrane antigen , in the treatment of advanced prostate cancer

Bull, J.M.rie C.; Scott, G.L.; Strebel, F.R.; Koch, S.M.; Oliver, D.; Raval, B., 2003:
Phase I trial of CISplatin , GEMcitabine , interferon-alpha , GM-CSF with fever-range, long-duration whole-body hyperthermia

Briasoulis, E.; Samantas, E.; Kalofonos, H.; Skarlos, D.; Christodoulou, C.; Fountzilas, G.; Bamias, A.; Dimopoulos, M.A.; Kosmidis, P.; Pavlidis, N., 2003:
Phase I trial of Cisplatin, Etoposide and CPT-11 triplet in patients with advanced stage SCLC A Hellenic Cooperative Oncology Group Study

Pisa, P.; Egevad, L.; Kiessling, R.; Lundqvist, A.; Masucci, G.; Nilsson, S.; Palmborg, A.; Pavlenko, M.; Roos, A.K.rin; Wersall, P., 2003:
Phase I trial of DNA immunization with PSA coding plasmid vector in patients with hormone-refractory prostate cancer

Kaufman, P.A.; Schwartz, G.; Dragnev, K.; Mulrooney, T.; Connelly, E.; Hazelton, S.; Lewis, L.; Cole, C.; Harris, R., 2002:
Phase I trial of Herceptin and Navelbine for patients with HER-2/neu advanced breast cancer

Friedman, H.S.; Pluda, J.; Bigner, D.D.; Pegg, A.E.; Moschel, R.C.; Cokgor, I.; Rich, J.; Friedman, A.H.; Dolan, M.E., 2000:
Phase I trial of O6-benzylguanine plus BCNU for patients with recurrent malignant glioma

Malkin, E.M.; Durbin, A.P.; Diemert, D.J.; Mcarthur, J.H.; Perreault, J.R.; Hisaeda, H.; Stowers, A.W.; Shimp, R.L.; Wang, J.; Miles, A.P.; Lambert, L.; Long, C.A.; Miller, L.H.; Saul, A., 2003:
Phase I trial of Pvs25h A transmission blocking vaccine for Plasmodium vivax malaria

Petak, I.; Tillman, D.M.; Stewart, C.; Turner, P.K.; Vernes, R.; Douglas, L.; Mihalik, R.; Sorrentino, B.P.; Schwartzberg, L.; Hougton, J.A., 2001:
Phase I trial of R-fluorouracil , leucovorin, and interferon-gamma based upon modulation of Fas signaling

Douillard, J.; Cosaert, J.; Barbarot, V., 2001:
Phase I trial of ZD0473 in combination with vinorelbine for patients with advanced cancer

D.B.no, J.S.; Hammond, L.A.; Figueroa, J.; Schwartzberg, L.; Ochoa, L.; Patnaik, A.; Olivo, N.; Schwartz, G.; Smith, L.; Ochs, J.; Rowinsky, E.K., 2002:
Phase I trial of ZD1839 in combination with 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer

Plummer, R.; Rees, C.; Judson, I.; Calvert, H.; Highley, M.; Trigo, J.; Jackman, A.; Smith, R.; Hutchison, M.; Smith, M., 1999:
Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks

Trigo, J.; Rees, C.; Beale, P.; Mitchell, F.; Jackman, A.; Smith, R.; Hutchison, M.; Smith, M.; Judson, I., 1999:
Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks

Muderspach, L.I.; Roman, L.D.; Facio, G.; Marty, V.; Bade, E.; Burnett, A.F.; Brader, K.R.; Morrow, C.P.ul; Felix, J.C.; Weber, J.S., 1999:
Phase I trial of a HPV-16 E7 peptide vaccine in women with high-grade cervical and vulvar dysplasia

Kublin, J.G.; Edelman, R.; Bodison, S.A.; Schmeckpeper, B.J.; Hamilton, R.G.; Diggs, C.L.; Nussenzweig, R.S.; Calvo Calle, J.M.; Oliveira, G.A.; Nardin, E.H., 1999:
Phase I trial of a Plasmodium falciparum map vaccine Delayed-type hypersensitivity skin test reactions to the map vaccine

Nemunaitis, J.; Cunningham, C.; Senzer, N.; Mao, J.; Sznol, M., 2003:
Phase I trial of a genetically attenuated Salmonella typhimurium expressing cytosine deaminase -CD administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced cancer

Conry, R.M.; Khazaeli, M.B.; Saleh, M.N.; Allen, K.O.; Barlow, D.L.; Moore, S.E.; Craig, D.; Arani, R.B.; Schlom, J.; LoBuglio, A.F., 1999:
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration

Briasoulis, E.; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, N., 1999:
Phase I trial of a three-day schedule of cisplatin plus topotecan

Zalutsky, M.R.; Cokgor, I.; Akabani, G.; Friedman, H.S.; Coleman, R.E.; Friedman, A.H.; Mclendon, R.E.; Reist, C.J.; Pegram, C.N.; Zhao, X.G.; Bigner, D.D., 2000:
Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients

Slovin, S.F.; Morrissey, D.M.; Gardner, J.P.; Donovan, G.P.; Surowitz, K.G.; Olson, W.C.; Scher, H.I.; Israel, R.J., 2004:
Phase I trial of an adjuvanted recombinant soluble prostate-specific membrane antigen vaccine

D.B.no, J.S.; Rowinsky, E.K.; Kuhn, J.; Ochoa, L.; Schwartz, G.; Patnaik, A.; Fingert, H.; Weitman, S.; Thompson, I.; Tolcher, A.W., 2001:
Phase I trial of bcl-2 antisense and docetaxel in hormone-refractory prostate cancer

Budd, G.T.omas; Peereboom, D.; Adelstein, D.; Wood, L.; Elson, P.; Bukowski, R., 2001:
Phase I trial of chemotherapy using amifostine for in vitro protection of GM-CSF primed peripheral blood progenitor cells

Katori, H.; Tsukuda, M.; Mochimatu, I.; Ishitoya, J.; Kawai, S.; Mikami, Y.; Matsuda, H.; Tanigaki, Y.; Horiuchi, C.; Ikeda, Y.; Taguchi, T.; Ono, M.; Yoshida, T.; Hirose, S.; Sakuma, Y.; Yamamoto, K., 2004:
Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced squamous cell carcinoma of the head and neck

Budd, G.T.; Peereboom, D.; Weiss, P.; Elson, P., 2001:
Phase I trial of continuous Taxotere, Adriamycin, and cyclophosphamide with G-CSF

Budd, G.T.omas; Peereboom, D.; Weiss, P.; Bukowski, R.; Elson, P., 2002:
Phase I trial of daily oral cyclophosphamide and weekly doxorubicin and docetaxel with filgrastim support

Rocha Lima, C.M.x S.; Catapano, C.; Sherman, C.A.; Brescia, F.J.; Oakhill, G.J.; Mushtaq, C.M.; Safa, A.R.; Bahadori, H.R.; Green, M.R., 2000:
Phase I trial of docetaxel , gemcitabine and irinotecan in patients with solid tumors

Szatrowski, T.; Hensley, M.; Ely, S., 1999:
Phase I trial of docetaxel for patients with relapsed or refractory acute myeloid leukemia

Lyass, O.; Hubert, A.; Tzemach, D.; Lafair, J.; Gabizon, A., 1999:
Phase I trial of doxil plus cisplatin in patients with advanced malignancies

Droz, J.P.erre; Roche, H.; Zanetta, S.; Terret, C.; Blay, J.Y.; Dumortier, A.; Kroon, K.; Wanders, J.; Ravic, M.; Fumoleau, P., 2000:
Phase I trial of five-days continuous infusion E 7070 - 1,4, benzene-disulfonanide in patients

Kreitman, R.J.; Hall, P.D.; Frankel, A.E., 2000:
Phase I trial of fusion toxin DTGM containing human GM-CSF fused to truncated diphtheria toxin in adults with relapsed or refractory acute myelogenous leukemia

Bander, N.H.; Nanus, D.; Goldsmith, S.; Kostakoglu, L.; Kuji, I.; Smith Jones, P.; Vallabhajosula, S.; Joyce, M.; Xia, J.; Kim, S., 2001:
Phase I trial of humanized monoclonal antibody to prostate specific membrane antigen/extracellular domain

Socinski, M.A.; Halle, J.; Morris, D.; Limentani, S.; Frazer, R.; Rosenman, J.G., 2002:
Phase I trial of induction and concurrent chemotherapy with dose-escalated Thoracic Conformal Radiation Therapy to 78 Gy and beyond in unresectable Stage III A/B Non Small Cell Lung Cancer

Flotte, T.R.; Zeitlin, P.L.; Reynolds, T.C.; Heald, A.E.; Pedersen, P.; Beck, S.; Conrad, C.K.; Brass Ernst, L.; Humphries, M.; Sullivan, K.; Wetzel, R.; Taylor, G.; Carter, B.J.; Guggino, W.B., 2003:
Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 -CFTR vector in adult cystic fibrosis patients A two-part clinical study

Dalbagni, G.; Russo, P.; Sheinfeld, J.; Mazumdar, M.; Tong, W.; Rabbani, F.; Donat, S.M.chelle; Herr, H.W.; Sogani, P.; Depalma, D.; Bajorin, D., 2002:
Phase I trial of intravesical gemcitabine in BCG-refractory transitional cell carcinoma of the bladder

Ferry, D.R.; Seymour, L.W.; Anderson, D.; Hesselwood, S.; Julyan, P.; Boivin, C.; Poyner, R.; Guest, P.; Doran, J.; Kerr, D.J., 1999:
Phase I trial of liver targeted HPMA copolymer of doxorubicin PK2, pharmacokinetics, SPECT imaging of 123I-PK2 and activity in hepatoma

Cokgor, I.; Akabani, G.; Friedman, A.; Coleman, R.E.; Zalutsky, M.; Mclendon, R.E.; Bigner, S.; Xiao Guang, Z.; Pegram, C.; Wikstrand, C.; Herndon, J.; Provenzale, J.; Friedman, H.S.; Bigner, D.D., 1999:
Phase I trial of newly diagnosed brain tumor patients treated with 131I-anti-tenascin Mab 81C6 via surgically created resection cavities

Hudes, G.R.; Schol, J., 2001:
Phase I trial of oral R115777 in patients with refractory solid tumors Preliminary results

Wille, A.H.; Johannsen, M.; Roigas, J.; Schnorr, D., 2004:
Phase I trial of paclitaxel and acarboplatin in advanced/metastatic transitional cell cancer

Bellmunt, J.; Baselga, J., 1999:
Phase I trial of paclitaxel, cisplatin, and gemcitabine in patients with advanced transitional cell carcinoma of the urothelium

Rizzieri, D.A.; Ibom, V.; Decastro, C.; Moore, J.O.; Payne, N.; Adams, D.; Adams, D.J.; Rosner, G.; Vredenburgh, J.J.; Gasparetto, C.; Long, G.; Chao, N.J.; Gockerman, J.P., 2001:
Phase I trial of prolonged infusion gemcitabine with fludarabine for relapsed/refractory acute leukemia

Urosevic, M.; Maier, T.; Morcinek, J.; Acres, B.; Bataille, V.; Burg, G.; Dummer, R., 2003:
Phase I trial of repeated intralesional injection of TG1042 in primary cutaneous T and B cell lymphomas

Grant, S.; Cragg, L.; Roberts, J.; Smith, M.; Feldman, E.; Winning, M.; Tombes, M., 1999:
Phase I trial of the PKC activator bryostatin 1 and F-ARA-AMP in patients with progressive CLL and refractory indolent non-Hodgkins lymphoma

Stevenson, J.P.; Gallagher, M.; Vaughn, D.; Schucter, L.; Haller, D.; Fox, K.; Algazy, K.; Aviles, V.; Hahn, S.; O'dwyer, P.J., 1999:
Phase I trial of the cryptophycin analogue LY355703 administered as an IV infusion, D1 and D8, repeated every 21 days

Tewes, M.; Schleucher, N.; Dirsch, O.; Schmid, K.W.rner; Arens, H.J.ergen; Seeber, S.; Harstrick, A.; Vanhoefer, U., 2002:
Phase I trial of the humanized anti epidermal growth factor receptor monoclonal antibody EMD 72000 in patients with EGFr expressing solid tumors

O'dwyer, P.; Stevenson, J.; Redlinger, M.; Sun, W.; Giantonio, B.; Hahn, S.; Algazy, K.; Burnite, M.; Koehler, M., 2001:
Phase I trial of the novel platinum analog ZD0473 in combination with gemcitabine in patients with advanced cancer

Roth, S.J.; Mayer, J.E.Jr.; Jonas, R.A.; Wessel, D.L.; Moore, S.E.; Richards, B.E.; Newburger, J.W., 1999:
Phase I trial of the selectin inhibitor CY-1503 in infants undergoing cardiopulmonary bypass surgery

Wagner,L.M.; Perentesis,J.P.; Reid,J.M.; Ames,M.M.; Safgren,S.L.; Nelson,M.D.,Jr.; Ingle,A.M.; Blaney,S.M.; Adamson,P.C., 2010:
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide for children with relapsed or refractory solid tumors a Childrens Oncology Group phase I consortium study

Scheibenbogen, C.; Keilholz, U.; Hoffmann, U.; Servetopoulou, F.; Schmittel, A.; Siehl, J.; Nagorsen, D.; Bauer, S.; Thiel, E.; Foerster, M.H.; Schadendorf, D., 2000:
Phase I trial of vaccination with tyrosinase peptides and different adjuvants in high-risk melanoma patients

Levine, A.M.; Quinn, D.I.; Gorospe, G.; Mohrbacher, A.; Weber, J.; Iqbal, S.; Tulpule, A., 2003:
Phase I trial of vascular endothelial growth factor-antisense in relapsed and refractory malignancies

Fumoleau, P.; Raymond, E.; Bennouna, J.; Armand, J.P.; Hocini, A.; Blanchot, G.; Pinel, M.C.; D.B.e, J.; Marty, M., 2001:
Phase I trial of vinflunine a novel fluorinated vinca alkaloid in patients with advanced solid malignancies Final results

Jurcic, J.G.; Divgi, C.R.; Mcdevitt, M.R.; Ma, D.; Sgouros, G.; Hamacher, K.A.; Finn, R.D.; Larson, S.M.; Scheinberg, D.A., 2000:
Phase I trial of yttrium-90-HuM195 in myeloid leukemia Potential for myeloablation

Reardon, D.A.; Akabani, G.; Friedman, A.; Friedman, H.; Herndon, J.; Mclendon, R.; Quinn, J.; Rich, J.; Penne, K.; Sampson, J.; Shafman, T.; Wong, T.; Zalutsky, M.; Bigner, D., 2002:
Phase I trial results Treatment of patients with newly diagnosed malignant gliomas using 131-iodine labeled human/murine chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities

Curran, W.J.; Dicker, A.P.; Komarnicky, L.T.; Anne, P.R.; Bonanni, R.; Sidor, C.; Fogler, W.; Folkman, J.; Gubish, E., 2001:
Phase I trial results of recombinant human angiostatin and radiotherapy

Oliveira, G.A.; Wetzel, K.; Calvo Calle, J.M.; Schmidt, A.; Birkett, A.; Gleiter, C.H.; Boehmer, G.M.; Kremsner, P.; Nussenzweig, V.; Nussenzweig, R.S.; Nardin, E., 2003:
Phase I trial to assess safety and immunogenicity of malarivax, a recombinant hepatitis virus core particle containing repeat and T cell epitopes Plasmodium falciparum circumsporozoite protein

Morris, M.J.; Divgi, C.; Kelly, W.K.; Slovin, S.; Solit, D.; Shaffer, D.; Halpern, J.; Delacruz, A.; Curley, T.; Nacca, A.; Smith Jones, P.; Finn, R., 2003:
Phase I trial to evaluate J591 as a vascular targeting agent in patients with advanced solid tumors

Punt, C.J.A.; Peters, M.; Van Maanen, L.; Van, D.W.lle, B.; Bol, C.; Willems, L.; Horak, I.; Palmer, P.; Wagener, D.J.T., 1999:
Phase I trial with farnesyltransferase inhibitor R115777 in patients with advanced solid tumors

Deb, G.; D.S.o, L.; Jenkner, A.; Castellano, A.; Helson, L.; Donfrancesco, A., 2000:
Phase I trial with paclitaxel according to the Q4D regimen in pediatric solid tumors

Rizzieri, D.A.; Akabani, G.; Zalutsky, M.; Coleman, R.E.ward; Toaso, B.; Anderson, E.; Lagoo, A.; Clayton, S.; Niedzwiecki, D.; Moore, J.O.; Gockerman, J.P.; Decastro, C.; Chao, N.J.; Gasparetto, C., 2003:
Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using 131I labeled chimeric anti-tenascin therapy for lymphoma

Fossella, F.V.; Gatzemeier, U., 2002:
Phase I trials of pemetrexed

Schmittel, A.; Scheibenbogen, C.; Keilholz, U.; Foerster, M.H.; Hofmann, U.; Servetopoulou, F.; Siehl, J.; Nagorsen, D.; Bauer, S.; Thiel, E.; Schadendorf, D., 2001:
Phase I trials of vaccination with peptides and different adjuvants in high-risk melanoma patients

Bergman, P.J.; Mcknight, J.; Houghton, A.N.; Dowd, M.; Craft, D.M.; Kang, X.; Riviere, I.; Hohenhaus, A.E.; Hicklin, D.J.; Wolchok, J., 2003:
Phase I trials of xenogeneic DNA vaccination with human tyrosinase or murine gp75 in client-owned dogs with advanced stage spontaneous malignant melanoma

Twelves, C.; Misset, J.L.; Villalona Calero, M.; Ryan, D.; Clark, J.; Beijnen, J.; Eder, P.; Supko, J.; Bowman, A.; Hoekman, H.; Brain, E.; Cvitkovic, E.; Guzman, C.; Jimeno, J., 1999:
Phase I trials with ET-743, a marine derived anticancer agent

Raymond, E.; Paz Ares, L.; Izquierdo, M.; Belanger, K.; Maroun, J.; Bowman, A.; Anthoney, A.; Jodrell, D.; Armand, J.P.; Cortes Funes, H.; Germa Lluch, J.; Twelves, C.; Celli, N.; Guzman, C.; Jimeno, J., 2001:
Phase I trials with aplidine , a new marine derived anticancer compound

Padma Nathan, H.; Pacik, J.S.ung; An, B.O.; Kang, K.K.o; Bahng, M.Y.ung; Kim, W.B.e, 2004:
Phase I, double-blind, placebo-controlled study in healthy male subjects to investigate the safety, tolerability, and pharmacokinetics of DA-8159

Langecker, P.; Blanchett, D.; Lang, W.; Pinkett, J.; Baenziger, C.; Schmit, A.; Brett, M.; Schubert, C.; Port, A., 2002:
Phase I, open-label, randomized, crossover study of the pharmacokinetic interaction of toremifene and atamestane in healthy postmenopausal women

Berlin, J.; Wahamaki, A.; Tutsch, K.D.; Alberti, D.; Feierabend, C.; Binger, K.; Arzoomanian, R.Z.; Volkman, J.; Kavka, J.; Marnocha, R.; Stewart, J.; Wilding, G., 1999:
Phase I, pharmacokinetic and bioavailability study of oral penclomedine administered daily times 5 every 4 weeks

Alberts, D.S.; Hallum, A.V.; Hatch, K.D.; Stratton Custis, M.; Carrier, A.; D.L.era, J.; Gleason Guzman, M.; Von Hoff, D.D.; Garcia, D.J.; Santabarbara, P.; Niesor, E.; Bentzen, C.C.; Floret, S., 2001:
Phase I, pharmacokinetic and in vitro chemosensitivity studies of APOMINE , a novel, oral anticancer drug

Clive, S.; Jodrell, D.I.; Maclellan, A.; Webb, D.J.; Young, A.; Miller, M.; Cummings, J.; Smyth, J.F., 1999:
Phase I, pharmacokinetic and pharmacodynamic study of Antagonist G, a broad spectrum neuropeptide growth factor antagonist

Ravoet, C.; Mineur, P.; Robin, V.; Debusscher, L.; Bosly, A.; Andre, M.; Housni, H.E.; Soree, A.; Martiat, P., 2002:
Phase I-II Study of a Farnesyl Transferase Inhibitor , SCH66336, in Patients with Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia

Faivre, S.; Raymond, E.; Lokiec, F.; Monnerat, C.; Novello, S.; Pautier, P.; Lhomme, C.; Kayitalire, L.; Armand, J.P.; L.C.evalier, T., 2001:
Phase I-II and pharmacokinetic study combining gemcitabine with oxaliplatin in patients with advanced non-small-cell lung and ovarian carcinoma

Chaoui, D.; Vekhoff, A.; Levy, V.; Morariu, R.; Legrand, O.; Blin, A.; Fromentin, D.; Robin, J.P.erre; Bardin, C.; Marie, J.P.erre, 2003:
Phase I-II clinical study of subcutaneous semi-synthetic homoharringtonine in induction treatment of relapsing/refractory myeloid leukemia An interim assessment

Sentenac, S.; Vekhoff, A.; Bardin, C.; Sandouk, P.; Jardin, M.; Marie, J.P.erre; Robin, J.P.erre; Chast, F., 2003:
Phase I-II pharmacokinetic study of subcutaneous semi-synthetic homoharringtonine in induction treatment of relapsing/refractory myeloid leukemia An interim assessment

Trudeau, M.E., 1999:
Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer

Airoldi, M.; Marchionatti, S.; Pedani, F.; Danova, M.; Recalenda, V.; Infante, L.; Cagliero, E.; Cattel, L., 2001:
Phase I-II study Clinical and pharmacokinetic data of docetaxel , carboplatin and concomitant radiotherapy in stage IV head and neck cancer

Fibich, C.; Fiedler, F.; Spohn, C.; Rohrberg, R.; Herold, M.; Schoeber, C.; Schmoll, H.J., 2000:
Phase I-II study of Mycophenolate-Mofetil in the treatment of steroid-refractory autoimmune thrombozytopenia and Evans-syndrome

Recchia, F.; D.F.lippis, S.; Saggio, G.; Amiconi, G.; Cesta, A.; Rea, S., 2003:
Phase I-II study of docetaxel, ifosfamide, cisplatin and 13-cis retinoic acid in locally advanced or recurrent squamous cell carcinoma of the head and neck

Fibich, C.; Rohrberg, R.; Sommer, H.; Dempke, W.; Schmoll, H.J., 2000:
Phase I-II study to evaluate safety and efficacy of Mycophenolate-Mofetil -treatment in refractory Evans-Syndrome

Pusztai, L.; Nealy, K.M.; Pallansch, P.; Rivera, E.; Valero, V.; Cristofanilli, M.; Hortobagyi, G.N., 2001:
Phase I-II study to evaluate safety and efficacy of capecitabine and exisulind combination therapy in patients with metastatic breast cancer

Schrijvers, D.; Van Herpen, C.; Kerger, J.; Joosens, E.; L.B.uder, C.; Castelijns, J.; Awada, A.; Vermorken, J.B., 1999:
Phase I-II study with docetaxel , cisplatin and 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck

Zorrilla, M.; Martinez Trufero, J.; Puertolas, T.; Corral, M.; Artal, A.; Herrero, A.; Alonso, V.; Anton Torres, A., 2000:
Phase I-II trial in locally advanced breast cancer with increased dose of continuous Orzel in combination with doxorubicin and paclitaxel every three weeks

Kuzel, T.; Breneman, D.; Duvic, M.; Truglia, J.; Yocum, R.; Stevens, V., 2000:
Phase I-II trial of Targretin gel in topical treatment of patients with cutaneous T-cell lymphoma

Curti, A.; Cellini, C.; Terragna, C.; Tosi, P.; Comoli, P.; Massaia, M.; Ferri, E.; Isidori, A.; Cavo, M.; Baccarani, M.; Lemoli, R.M., 2003:
Phase I-II trial of anti-cancer vaccination for multiple myeloma patients using dendritic cells pulsed with tumor idiotype or Id -derived peptides

Massuti, B.; Barneto, I.; Meana, J.A.; Herrero, J.; Pico, C.; Aranda, E.; Garcia, M.A.; D.L.G.ndara, I., 1999:
Phase I-II trial of carboplatin an vinorelbine in stage IV non-small cell lung cancer A pilot study of Spanish Lung Cancer Group

Chevreau, C.; Bui, B.N.uyen; Chevallier, B.; Krakowski, I.; Maugard, C.; Mihura, J.; Coindre, J.M.chel; Gil, B.; Cour Chabernaud, V., 1999:
Phase I-II trial of intensification of the MAID regimen with support of lenograstim in patients with advanced soft-tissue sarcoma

Recchia, F.; Defilippis, S.; Rosselli, M.; Saggio, G.; Pompili, P.L.; Cesta, A.; Rea, S., 2000:
Phase I-II trial of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced cancer

Sparano, J.A.; Malik, U.; Wolff, A.; Rajdev, L.; Sarta, C.; Hopkins, U., 2000:
Phase I-II trial of pegylated liposomal doxorubicin plus docetaxel in patients with advanced breast cancer

Barbanoj, M.J.; Antonijoan, R.M.; Garcia Gea, C.; Valle, M.; Jane, F., 2003:
Phase I-IIa in neuropsychopharmacology Is the proof of concept feasible?

Hoffmeyer, A.; Kroeger, J.C.; Holle, A.; Mueller, P.; Wagner, T.; Guenzburg, W.H.; Salmons, B.; Hauenstein, K.H.; Liebe, S.; Loehr, M., 1999:
Phase I-Study for patients with inoperable pancreatic carcinoma with encapsulated cells producing cytochrome P450 CYP2B1 that activates ifosfamide

Schoeffski, P.; Hagedorn, T.; Gruenwald, V.; Paul, H.; Merkle, K.; Kowalski, R.; Ganser, A., 1999:
Phase I-study of bendamustine-HCl in patients with solid tumors

Loehr, M.; Hoffmeyer, A.; Kroeger, J.; Holle, A.; Mueller, P.; Hain, J.; Saller, R.; Wagner, T.; Guenzburg, W.; Salmons, B.; Liebe, S.; Hauenstein, K.H., 2001:
Phase I-study with encapsulated cells genetically modified to produce the ifosfamide activating cytochrome P 450 2B1 in pancreatic carcinoma

Lshr, M.; Anne, H.; Krsger, J.C.; Holle, A.; Mueller, P.; Hain, J.; Saller, R.M.; Wagner, T.; Guenzburg, W.H.; Salmons, B.; Liebe, S.; Hauenstein, K., 2000:
Phase I-study with encapsulated cells genetically modified to produce the ifosfamide activating cytochrome P 450 2B1 in patients with inoperable pancreatic carcinoma

Mauro, M.J.; Deininger, M.W.; O'dwyer, M.E.; Maziarz, R.T.; Walker, T.; Kurilik, G.; Druker, B.J., 2002:
Phase I/II Study of Arsenic Trioxide in Combination with Imatinib Mesylate in Patients with Gleevec-Resistant Chronic Myelogenous Leukemia in Chronic Phase

Gotlib, J.; Loh, M.; Vattikuti, S.; Dugan, K.; Quesada, S.; Katamneni, U.; Sridhar, K.; Wright, J.; Thibault, A.; Rybak, M.E.; Shannon, K.; Greenberg, P.L., 2002:
Phase I/II Study of ZARNESTRATM in Patients with Myeloproliferative Disorders Preliminary Results

Ogura, M.; Kikuchi, A.; Kawase, T.; Kajimoto, K.; Kamiya, Y.; Taji, H.; Kagami, Y.; Morishima, Y., 2002:
Phase I/II Study of a New Salvage Chemotherapy with Rituximab for Relapsed Advanced Follicular Lymphoma and Mantle Cell Lymphoma

Leonard, J.P.; Coleman, M.; Matthews, J.C.; Chadburn, A.; Wegener, W.A.; Hansen, H.J.; Ziccardi, H.; Kapushoc, H.; Gayko, U.; Cesano, A.; Fields, S.Z.; Goldenberg, D., 2002:
Phase I/II Trial of Epratuzumab in Non-Hodgkins Lymphoma

Krzakowski, M.; Ramlau, R.; Pinel, M.; Zorza, G.; Colin, C.; Souquet, P., 2003:
Phase I/II and pharmacokinetic study of vinflunine in combination with cisplatin for treatment of advanced non-small cell lung cancer in chemonaive patients Preliminary results

Waksal, Harlan, W., 2000:
Phase I/II clinical effects of C225, a chimerized antibody to the epidermal growth factor receptor , in head and neck squamous cell carcinoma

Komatsu, Y.; Takeda, H.; Kato, M.; Sugiyama, T.; Asaka, M.; Miyagishima, T.; Kunieda, Y.; Tateyama, M.; Sakata, Y., 2001:
Phase I/II clinical trial on the combination chemotherapy with CPT-11 and the new oral anticancer drug S-1 for Advanced Gastric Cancer

Alexander, A.N.rdstrom; Huelsmeyer, M.K.; Vail, D.M.; Kurzman, I.D.; Macewen, E.G.egory, 2002:
Phase I/II clinical trial utilizing a tumor cell vaccine encoding xenogeneic Gp100 in canine patients with metastatic melanoma Immunological and clinical outcomes

Latreille, J.; Laberge, F.; Riviere, M.; Falardeau, P.; Champagne, P.; Croteau, D.; Dupont, E.; Chum, C.L.vinton And, C., 1999:
Phase I/II clinical trials of escalating dose of AE-941, an inhibitor of angiogenesis, in patients with refractory lung cancer

Weihrauch, M.R.; Jurkiewicz, E.; Geisen, C.; Xia, Z.; Anderson, K.S.; Diehl, V.; Wolf, J.; Bohlen, H.; Nadler, L.M., 2003:
Phase I/II combined immuno-/chemotherapy with CEA derived HLA-A2 restricted CAP-1 peptide and irinotecan, 5-fluorouracil and leucovorin in patients with primary metastatic colorectal cancer

Urbano, M.T.G.errero; Clark, C.; Miles, E.; Bidmead, M.; Harmer, C.; Harrington, K.; Nutting, C., 2003:
Phase I/II dose escalation study of intensity modulated radiotherapy in cancer of the thyroid, larynx and hypopharynx Report of acute toxicity

Clemons, M.J.; Tye, L.M.; Marques, R.; Brennan, J.; Reid, C.; Kirkbride, P.; Fyles, A.; Young, S.D.; Hayes, L.; Crump, M.; Goss, P.E., 1999:
Phase I/II dose-escalation study of liarozole plus tamoxifen in postmenopausal women with metastatic breast cancer

Ashamalla, H.; Zaki, B.; Nasr, H.; Colella, F.; Dosik, D.; Krishnamurthy, M.; Vance, W.; Saad, N.; Guriguis, A., 2003:
Phase I/II fractionated stereotactic radiotherapy and weekly paclitaxel in malignant gliomas

Hercbergs, A.A.; Goyal, L.K.; Suh, J.H.; Reddy, C.A.; Cohen, B.; Stevens, G.H.J.; Reddy, S.; Crownover, R.; Elson, P.; Barnett, G.H., 2000:
Phase I/II high-dose tamoxifen dose escalation study in combination with reduction of thyroid hormone levels in failed malignant glioma patients

Siebels, M.; Rohrmann, K.; Oberneder, R.; Hofstetter, A.; Varga, Z.; Hoffmann, R.; Kindler, M.; Melchior, S.; Mala, C.; Beck, J., 2004:
Phase I/II multicentre study with the monoclonal antibody WX-G250 in combination with interferon alpha-2a in metastatic renal cell carcinoma

Fabel Schulte, K.; Dietrich, J.; Hau, P.; Wismeth, C.; Angerer, M.; Bogdahn, U., 2000:
Phase I/II pilot study of liposomal doxorubicin in the treatment of recurrent high-grade gliomas

Steins, M.B.; Padro, T.; Bieker, R.; Ruiz, S.; Buerger, H.; Kropff, M.; Kienast, J.; Berdel, W.E.; Mesters, R.M., 2000:
Phase I/II pilot study of the safety and efficacy of thalidomide in patients with relapsed or refractory acute myeloid leukemia

Hajjar, G.; Burton, J.D.; Sharkey, R.M.; Schuster, S.L.; Czuczman, M.; Lamonica, D.; Chatal, J.F.; Alavi, A.; Stadtmauer, E.; Leonard, J.P.; Coleman, M.; Goldenberg, D.M., 2001:
Phase I/II radioimmunotherapy trial with 90Y-labeled Epratuzumab in relapsed/refractory non-Hodgkins lymphoma

Davis, I.; Cebon, J.; Parente, P.; Shackleton, M.; Hopkins, W.; Masterman, K.A.ne; Jefford, M.; Chen, Q.; Jackson, H.; Chen, W.; Luft, T.; Sturrock, S.; Macgregor, D.; Caron, D.; Maraskovsky, E., 2002:
Phase I/II randomized study of flt 3 ligand with or without vaccination in HLA-A2+ patients with stage III and stage IV malignant melanoma

Jones, E.; Brizel, D.; Dewhirst, M.; Alvarez, A.; Berchuck, A.; Clarke Pearson, D.; Rodriquez, G.; Soper, J.; Prosnitz, L., 2001:
Phase I/II results using concurrent hyperthermia, radiotherapy, and chemotherapy for cervix cancer

Petrylak, D.P.; Macarthur, R.; O'connor, J.; Shelton, G.; Weitzman, A.; Judge, T.; England Owen, C.; Zuech, N.; Pfaff, C.; Newhouse, J.; Bagiella, E.; Hetjan, D.; Sawczuk, I.; Benson, M.; Olsson, C., 1999:
Phase I/II studies of docetaxel combined with estramustine in men with hormone-refractory prostate cancer

Apostolidou, E.; List, A.F.; Roboz, G.J.; Feldman, E.J.; Rae, P.E.; Dugan, M.; Reitsma, D.; Laurent, D.; Kantarjian, H.; Giles, F.J., 2003:
Phase I/II study PTK787/ZK 222584 in patients with myelofibrosis

Moreland, L.; Chase, W.; Fife, R.; Hillson, J.; Greco, T.; Korn, J.; Tesser, J.; Weisman, M.; Rhil 11 R.S.udy Group; King, K.; Lyons, D.; Gugliotti, R., 1999:
Phase I/II study evaluating the safety and potential efficacy of recombinant interleukin-11 in patients with refractory rheumatoid arthritis

Heilmann, V.; Burges, A.; Gropp, M.; Pfisterer, J.; Schmalfeldt, B.; Richter, B.; Jackisch, C.; Staehle, A.; Kimmig, R.; D.B.is, A., 2003:
Phase I/II study of PLD and carboplatin in patients with advanced gynaecological carcinomas An interim analysis of the GYN II trial of the AGO ovarian cancer study group

Giles, F.J.; List, A.F.; Roboz, G.J.; Tsimberidou, A.M.ria; Laurent, D.; Reitsma, D.; Kowalski, M.O.; Kantarjian, H.; Feldman, E.J., 2003:
Phase I/II study of PTK787/ZK 222584 , a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaplasia

Dent, J.; Dodwell, D.; Bradley, C.; Joffe, J.; Crawford, M.; Hallam, S.; Perren, T.J., 1999:
Phase I/II study of Taxotere in combination with epirubicin and protracted venous infusion 5-fluorouracil in patients with recurrent or metastatic breast cancer A Yorkshire collaborative breast cancer study

Gotlib, J.; Loh, M.; Lancet, J.E.; Vattikuti, S.; Quesada, S.; Dugan, K.; Katamneni, U.; Sridhar, K.; Wright, J.; Thibault, A.; Rybak, M.E.; Shannon, K.M.; Greenberg, P.L., 2003:
Phase I/II study of Tipifarnib R115777 in patients with myeloproliferative disorders

Tomita, N.; Fukunaga, M.; Uedo, N.; Ishihara, R.; Ishida, H.; Furukawa, H., 2002:
Phase I/II study of a combination of CPT-11 and UFT-E in patients with advanced/recurrent colorectal cancer Osaka gastrointestinal cancer chemotherapy study group Protocol 0102

Ansell, S.; Byrd, J.; Horwitz, S.; Davis, T.; Borchmann, P.; Engert, A.; Strair, R.; Khan, K.; Keler, T.; Graziano, R.; Blanset, D.; Yellin, M.; Nichol, G., 2003:
Phase I/II study of a fully human anti-CD30 monoclonal antibody in Hodgkins disease and anaplastic large cell lymphoma

Dunleavy, K.M.; Janik, J.; Grant, N.; White, T.; Pittaluga, S.; Jaffe, E.S.; Staudt, L.; Wilson, W.H., 2003:
Phase I/II study of bortezomib combined with dose adjusted-EPOCH chemotherapy in relapsed or refractory diffuse large B-cell lymphomas

Gruber, M.L.; Glass, J., 2000:
Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme

Jones, P.H.; Elliot, M.; Dobbs, N.; Kakkar, A.J.; Talbot, D.C.; Ganesan, T.S.; Harris, A.L., 1999:
Phase I/II study of combination antiangiogenesis therapy with marimastat, captopril and fragmin

Brierley, J.D.; Oza, A.M.; Wong, C.S.; Ringash, J.; Catton, P.; Siu, L.; Hedley, D.; Feld, R.; Maclean, M.; Moore, M., 2001:
Phase I/II study of combined modality therapy in pancreatic cancer with gemcitabine and escalating dose radiation therapy

Kato, S.; Sakura, M.; Kazumoto, T.; Sakai, H.; Yoneda, S.; Noguchi, Y.; Kobayashi, K.; Honda, S.; Kosaihira, S., 2001:
Phase I/II study of docetaxel and carboplatin with concurrent radiotherapy in patients with stage III unresectable non-small cell lung cancer , preliminary results

Thomas, X.; Cambier, N.; Taksin, A.L.; Reman, O.; Vekhoff, A.; Pautas, C.; Leblond, V.; Soler Michel, P.; Ecstein Fraisse, E.; Archimbaud, E., 2000:
Phase I/II study of escalating doses of mitoxantrone in a single injection combined with timed sequential therapy in patients with refractory or relapsed acute myeloid leukemia

Bayne, M.; Zivanovic, M.; Lewington, V.; Du, Y.; Harrison, C.; Hodges, L.; Johnson, P.; Illidge, T., 2003:
Phase I/II study of fractionated radioimmunotherapy in relapsed low grade non Hodgkins lymphoma

Lorusso, V.; Catino, A.; Mancarella, S.; D'amico, C.; Latrorre, A.; Guida, M.; Sambiasi, D.; D.L.na, M., 1999:
Phase I/II study of gemcitabine plus mitoxantrone in advanced breast cancer

Chang, A.Y.; Rubins, J., 1999:
Phase I/II study of gemcitabine, navelbine, and cisplatin in advanced breast cancer and non-small-cell lung cancer

Zomas, A.; Marinakis, T.; Gortzolidis, G.; Hytiroglou, K.; Michalis, E.; Galanopoulos, A.; Tsakri, A.; Skandalis, A.; Anagnostopoulos, N.I., 2003:
Phase I/II study of immunosuppression with mycophenolate mofetil in elderly patients with autoimmune cytopenias

Borish, L.C.; Nelson, H.S.; Corren, J.; Bensch, G.; Busse, W.; Whitmore, J.; Agosti, J., 2000:
Phase I/II study of interleukin-4 receptor in adults with moderate asthma

Komatsu, Y.; Takei, M.; Kato, T.; Miyagishima, T.; Kunieda, Y.; Tateyama, M.; Wakahama, O.; Takeda, H.; Kato, M.; Sugiyama, T.; Asaka, M.; Sakata, Y., 2002:
Phase I/II study of irinotecan combined with I-leucovorin and 5FU in patients with advanced colorectal cancer

Ramon, Y.Cajal, T.; Rayo, S.G.rcia; Calvo, E.; Aristu, J.J.; Villafranca, E.; Canon, R.; Moreno, M.; Hernandez, J.L.; Azinovic, I., 1999:
Phase I/II study of oxaliplatin plus 5-Fluorouracil concurrent with external beam radiotherapy in rectosigmoid carcinoma

Mauer, A.M.; Ansari, R.H.; Hoffman, P.C.; Tembe, S.A.; Gabrys, G.T.omas; Szeto, L.; Vokes, E.E., 1999:
Phase I/II study of paclitaxel, ifosfamide, and carboplatin with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer

Borish, L.C.; Nelson, H.S.; Corren, J.; Bensch, G.; Busse, W.; Whitmore, J.; Agosti, J., 2000:
Phase I/II study of recombinant interleukin-4 receptor in adult patients with moderate asthma

Kanamaru, R.K.; Yoshioka, T.Y.; Ishioka, C.I.; Murakawa, Y.M.; Shibata, H.S.; Suzuki, T.S.; Kato, S.K.; Satake, N.S.; Sakayori, M.S., 2001:
Phase I/II study of the new combination chemotherapy with cis-diammine-glycolatoplatinum and 5-fluorouracil for advanced esophageal cancers

Byrd, J.C.; Grever, M.R.; Davis, B.; Lucas, M.S.; Park, K.; Goodrich, A.; Morrison, C.; Murphy, T.; Kunkel, L.; Grillo Lopez, A.; Waselenko, J.K.; Flinn, I.W., 1999:
Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia /small lymphocytic lymphoma A feasible and active regimen

Kruit, W.H.J.; Van Baren, N.; Humblet, Y.; Punt, C.J.A.; Avril, M.F.; Escudier, B.; Aamdal, S.; Eggermont, A.M.M.; Hakansson, L.; Keilholz, U.; Lehmann, F.; Gerritsen, W.; Scheibenbogen, C.; Van Der Bruggen, P.; Wolfel, T.; Guequen, M.; Wanders, J.; Uiters, J.; Delire, M.; Stoter, G.; Marchand, M., 2000:
Phase I/II study of vaccination with a MAGE-3 protein plus immunological adjuvant SB AS-2 in HLA class I selected patients with MAGE-3 positive tumors

Arnaudov, G.; Lissitchkov, T.; Peytchev, D.; Ganeva, P.; Merkle, K., 2003:
Phase I/II study to evaluate DLT, MTD and tolerability of bendamustine in pre-treated patients with advanced; relapsed or refractory B-CLL

Knop, S.; Straka, C.; Hebart, H.; Haen, M.; Kanz, L.; Einsele, H., 2003:
Phase I/II study with bendamustine hydrochloride in patients with multiple myeloma relapsing after high dose therapy and autologous stem cell transplantation

Herbst, R.S.; Mininberg, E.; Henderson, T.; Kim, E.; Hong, W.K.; Mass, R.; Novotny, W.; Garcia, B.; Johnson, D.; Sandler, A., 2003:
Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer

Teh, B.S.; Ayala, G.E.; Mai, W.; Vlachaki, M.T.; Caillouet, J.; Davis, M.; Wheeler, M.M.; Wheeler, T.M.; Miles, B.J.; Kadmon, D.; Aguilar Cordova, L.; Woo, S.Y.; Carpenter, L.S.; Chiu, J.K.; Lu, H.H.; Thompson, T.C.; Aguilar Cordova, E.; Butler, E.B., 2002:
Phase I/II trial evaluating combined radiotherapy and in-situ gene therapy with or without hormonal therapy in the treatment of prostate cancer An interim report on PSA response and biopsy data

Teh, B.S.; Aguilar Cordova, E.; Kernan, K.; Miles, B.; Mai, W.Y.; Caillouet, J.; Chou, C.C.; Ayala, G.; Wheeler, T.; Shalev, M.; Kadmon, D.; Vlachaki, M.; Thompson, T.; Butler, E.B., 2000:
Phase I/II trial evaluating combined radiotherapy and in-situ gene-therapy with or without hormonal therapy in the treatment of prostate cancer A preliminary report

Eickhoff, A.; Jakobs, R.; Martin, W.R.; Riemann, J.F., 2002:
Phase I/II trial of Gemcitabine and Epirubicin in patients with advanced pancreatic carcinoma

Galanis, E.; Okuno, S.; Lewis, B.; Oliveira, A.; Nascimento, A.; Sloan, J.; Edmonson, J.; Randlev, B.; Uprichard, M.; Rubin, J., 2001:
Phase I/II trial of ONYX-015 in combination with chemotherapy in patients with advanced sarcomas

Marin, D.; Ranger, A.; Kaeda, J.; Avery, S.; Nadal, E.; Nathan, I.; Burton, C.H.; Apperley, J.F.; Goldman, J.M., 2003:
Phase I/II trial of adding semi-synthetic homoharringtonine in CML patients who have achieved complete cytogenetic response on imatinib

Faller, D.V.; Hermine, O.; Small, T.; O'reilly, R.; Fingeroth, J.; Mentzer, S.J.; Perrine, S.P., 2000:
Phase I/II trial of arginine butyrate to induce viral TK gene expression in Epstein-Barr virus -associated lymphomas

Thumma, S.; Hari, P.; Bredeson, C.; Drobyski, W.; Flomenberg, N.; Horowitz, M.M.; Johnson, V.P.; Keever Taylor, C.; Phillips, G.L.; Reece, D.E.; Rizzo, J.D.uglas; Wade, J.C.; Vesole, D., 2003:
Phase I/II trial of dose escalation of melphalan with amifostine cytoprotection supported by autologous hematopoietic stem cell transplant in multiple myeloma patients gtoreq65 years

Nelli, F.; D.M.rinis, F.; Ariganello, O.; Belli, R.; Cipri, A.; Diana, F.; Lampignano, M.; Paoluzzi, L.; Martelli, O.; Migliorino, M.R.; D.M.lfetta, M., 2002:
Phase I/II trial of gemcitabine administered every other week plus cisplatin in advanced non-small cell lung cancer Final results

Kroger, N.; Kiehl, M.; Schwerdtfeger, R.; Renges, H.; Kruger, W.; Zabelina, T.; Rischewski, J.; Togel, F.; Wittkowsky, G.; Kuse, R.; Hegewisch Becker, S.; Zander, A., 2001:
Phase I/II trial of high-dose chemotherapy with autograft followed by dose-reduced allograft for multiple myeloma stage II/III

Socinski, M.A.; Halle, J.; Clark, J.; Fraser, R.; Limentani, S.; Mitchell, W.; Schell, M.; Rosenman, J., 1999:
Phase I/II trial of induction carboplatin /paclitaxel followed by dose-escalating thoracic conformal radiation therapy and concurrent carboplatin/paclitaxel in unresectable stage III non-small cell lung cancer

Socinski, M.A.; Sandler, A.B.; Miller, L.L.; Israel, V.K.; Hanover, C.K.; Locker, P.K.; Erling, G.L.; Natale, R.B., 2000:
Phase I/II trial of irinotecan , paclitaxel , and carboplatin in advanced or metastatic non-small cell lung cancer

Sampson, J.H.; Cokgor, I.; Akabani, G.; Friedman, A.H.; Coleman, R.E.; Zalutsky, M.R.; Mclendon, R.E.; Bigner, S.H.; Xiao Guang, Z.; Pegram, C.N.; Wilstrand, C.J.; Herndon, J.E.IIi; Provenzale, J.M.; Friedman, H.S.; Bigner, D.D., 1999:
Phase I/II trial of newly dianosed brain tumor patients treated with 131I-anti-tenascin MAb 81C6 via surgically created resection cavities

Badros, A.Z.; Ratterree, B.; Natt, S.; Rapoport, A.P.; Zeldis, J.B.; Frankel, S.R.; Meisenberg, B.; Takebe, N.; Zwiebel, J.A.; Zhang, B.; Fenton, R., 2003:
Phase I/II trial of oblimersen sodium , dexamethasone and thalidomide in patients with relapsed multiple myeloma

Klaassen, U.; Lang, S.; Borquez, D.; Oberhoff, C.; Benner, S.; Harstrick, A.; Seeber, S., 1999:
Phase I/II trial of oral UFT/Leucovorin and paclitaxel in the second line treatment of patients with metastatic breast cancer

Socinski, M.A.; Miller, L.L.; Sandler, A.B.; Israel, V.K.; Hanover, C.K.; Locker, P.L.; Elfring, G.L.; Natale, R.B., 1999:
Phase I/II trial of paclitaxel , carboplatin , and irinotecan in advanced, metastatic non-small cell lung cancer

Sandler, A.B.; Socinski, M.A.; Natale, R.B.; Hanover, C.K.; Miller, L.L., 1999:
Phase I/II trial of paclitaxel, carboplatin, and irinotecan in advanced or metastic non-small-cell lung cancer

Roedel, C.; Grabenbauer, G.G.; Hohenberger, W.; Papadopoulos, T.; Sauer, R., 2003:
Phase I/II trial of preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer

Ferrari, A.C.; Chachoua, A.; Rosenthal, M.; Stone, N.; Stock, R.; Kirschenbaum, A.; Taneja, S.; Utate, M.; Baldwin, Y.; Kutz, L.; Lepor, H.; Muggia, F., 2000:
Phase I/II trial of weekly taxol and estramustine in patients with hormone-refractory prostate cancer

Uberti, J.P.; Ayash, L.; Levine, J.E.; Silver, S.; Reddy, P.; Becker, M.; Reynolds, C.; Cooke, K.; Ratanatharathorn, V.; Ferrara, J., 2003:
Phase I/II trial on the use of etanercept and solumedrol as primary treatment for acute graft-vs-host disease

Argiris, A.; Peccerillo, K.; Murren, J.R.; Cornelius, E.; Modlin, I.M., 2000:
Phase I/II trial with 111In-pentetreotide in patients with advanced malignancies

Espigado, I.; Marín-Niebla, A.; Rovira, M.; Juliá, A.; Rodríguez, J.M.; Altés, A.; Arranz, R.; Bargay, J.; Diez, J.L.; Forés, R.; Morales, A.; Graus, F.; Messague, I.; Hernández, J.C.; Parody, R.; Richard, C.; Ferrá, C.; García, A.; Carreras, E., 2003:
Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experience

Friedman, H.S.; Cokgor, I.; Kerby, T.; Rasheed, K.; Lovell, S.; Affronti, M.L.u; Lawless, A.; Edwards, S.; Lawyer, J.; Stewart, B.; Mclendon, R.; Bigner, D.D.; Colvin, O.M.chael; Provenzale, J.; Modrich, P.; Friedman, A.H., 1999:
Phase I/II trials of malignant glioma with CPT-II plus BCNU, CPT-11 plus topotecan, or temozolomide

Genton, B.; A.Y.man, F.; Betuela, I.; Anders, R.; Saul, A.; Ginny, M.; Taraika, J.; Brown, G.; Smith, T.; Beck, H.P.; Felger, I.; Sturchler, D.; Alpers, M.P., 1999:
Phase I/II trials with a three-component blood-stage vaccine against Plasmodium falciparum malaria in Papua New Guinea

Jabboury, K.; Wong, A.; Hendricks, S.; Garcia, O.; Habboubi, N., 1999:
Phase I/II weekly sequential trimetrexate and 24-hour fluorouracil/leucovorin infusion in advanced malignancy

Richie, T.L.; Luke, T.C.; Epstein, J.E.; Kumar, S.; Wang, R.; Charoenvit, Y.; Aguiar, J.; Sedegah, M.; Gray, G.; Parker, S.E.; Weiss, W.; Hobart, P.; Kradjian, S.; Norman, J.A.; Hoffman, S.L., 2000:
Phase I/IIa study of safety, tolerability, immunogenicity and efficacy of MuStDO 5, a five gene sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA

Stevenson, J.P.ilip; Gallagher, M.; Sun, W.; Algazy, K.; Vaughn, D.J.; Haller, D.G.; Hiller, K.; Halloran, L.; O'dwyer, P.J., 2000:
Phase I/pharmacokinetic trial of the endothelial toxin combretastatin A4P administered as an IV bolus on a daily X 5 schedule every 21 days

Vasudeva, Rishi, S., 2000:
Phase II Can protein-based polymers replace petrochemical polymers in disposable diapers?

O'connor, O.A.; Moskowitz, C.H.; Wright, J.J.; Macgregor Cortelli, B.; Straus, D.; Furst, D.; Horse Grant, D.; Schenkein, D.P.; Zelenetz, A.D., 2002:
Phase II Clinical Experience with the Proteasome Inhibitor PS-341 in Patients with Indolent Lymphomas

Langer, C.; Adak, S.; Thor, A.; Vangel, M.; Johnson, D., 2001:
Phase II Eastern Cooperative Oncology Group pilot study of paclitaxel , carboplatin , and trastuzumab in HER-2/neu advanced non-small cell lung cancer Early analysis of e2598

Drapkin, R.; D.B.lla, N.J.; Cuasay, L.C.; Edelman, G.; Richards, D.; Mirabel, M.; Asmar, L., 2002:
Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Previously Treated or Untreated Chronic Lymphocytic Leukemia

Goy, A.; Sarris, A.H.; Bleyer, A.; Duvic, M.; Mesina, O.; Dang, N.H.; Fayad, L.; Hagemeister, F.; Mclaughlin, P.; Pro, B.; Rodriguez, M.A.; Romaguera, J., 2002:
Phase II Study of Compound GW506U78 in Patients with T-Cell and B-Cell Non Hodgkin Lymphomas

Dang, N.H.; Hagemeister, F.B.; Fayad, L.; Pro, B.; Mclaughlin, P.; Romaguera, J.E.; Samaniego, F.; Younes, A.; Goy, A.; Preti, A.; Jones, D.; Sarris, A.; East, K.; Rodriguez, M.A.; Cabanillas, F., 2002:
Phase II Study of Delineukin Diftitox for Relapsed/Refractory B and T-Cell Non-Hodgkins Lymphoma

Venugopal, P.; Gregory, S.A.; Shammo, J.; O'brien, T.; O'donnell, K.; Porter, C., 2002:
Phase II Study of Gemcitabine, GMCSF and Rituximab Combination in Relapsed/Refractory Lymphoma-Proliferative Disorders Efficacy and Safety Profile

Venugopal, P.; Gregory, S.A.; Raza, A.; Adler, S.; Enschede, S.; Manson, S.D.; Rogers, K.; Hsu, W.T.ng; Sivaraman, S.; Loew, J., 2002:
Phase II Study of Gemtuzumab Ozogamycin Combined with Intensive Induction Chemotherapy Using High Dose ara-C and Mitoxantrone Followed by Amifostine in Poor Prognosis Acute Myeloid Leukemia Preliminary Results

Piga, A.; Galanello, R.; Cappellini, M.D.; Forni, G.L.ca; Opitz, H.; Ford, J.M.; Sechaud, R.; Mueller, C.; Donato, G.; Alberti, D., 2002:
Phase II Study of Oral Chelator ICL670 in Thalassaemia Patients with Transfusional Iron Overload Efficacy, Safety, Pharmacokinetics and Pharmacodynamics after 6 Months of Therapy

Venugopal, P.; Gregory, S.A.; Wooldridge, J.; Yunus, F.; Adler, S.; Shammo, J.; Enschede, S.; O'brien, T.; Franson, P.; Porter, C., 2002:
Phase II Study of Rituximab in Combination with CHOP Chemotherapy and GMCSF in Patients with Previously Untreated Aggressive Non-Hodgkins Lymphoma

Sacchi, S.; Tucci, A.; Merli, F.; Orsucci, L.; Cervetti, G.; Occhini, U.; Liberati, M.; Tarantini, G.; Callea, V.; Brugiatelli, M.; Lauta, V.M.chele; Baldini, L, 2002:
Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab in Relapsed Follicular Lymphoma Patients

Parmar, S.; Rundhaugen, L.M.; Boehlke, L.L.; Riley, M.B.th; Nabhan, C.; Raji, A.; Tallman, M.S., 2002:
Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia , Secondary Leukemia, and/or Newly Diagnosed Patients 65 Years Old

Venkatesh, H.; D.B.lla, N.J.; Cuasay, L.C.; Vellek, M.; Mirabel, M.; Asmar, L., 2002:
Phase II Trial of Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkins Lymphoma

Bentzen, J.D.; Hansen, H.S., 2003:
Phase II analysis of Taxol and Capecitabine in the treatment of recurrent or disseminated, squamous cell carcinoma of the head and neck region

Prados, M.D., 1999:
Phase II and III trials with temozolomide, including clinical trials in patients with brain tumors

Raymond, E.; Campone, M.; Stupp, R.; Menten, J.; Chollet, P.; Lesimple, T.; Paoletti, X.; Lacombe, D.; Fumoleau, P., 2002:
Phase II and pharmacokinetic multicentre study of RFS 2000 administered orally as a 5-day-on 2-day-off schedule in patients with glioblastoma multiforme

Bjarnason Wehrens, B.; Mccabe, M.; Benesch, L.; Bischoff, K.O.; Kilian, B.B.ran; Gysan, D.; Hollenstein, U.; Mayer Berger, W.; Wilkniss, R.; Sauer, G., 2003:
Phase II cardiac rehabilitation carried out on an out-patients basis in patients with low social status

Fabian, C.J.; Kimler, B.F.; Brady, D.; Zalles, C.M.; Mayo, M.S.; Masood, S.; Grizzle, W.E., 2000:
Phase II chemoprevention trial of DFMO using the random FNA model

Kimler, B.F.; Zalles, C.M.; Masood, S.; Kitchen, J.; Grizzle, W.E.; Arneson, D.W.; Mayo, M.S.; Fabian, C.J., 2001:
Phase II chemoprevention trial of alpha-DiFluoroMethylOrnithine in women at high risk for breast cancer Surrogate endpoint biomarkers

Arun, B.; Babiera, G.; Lammey, J.; Hortobagyi, G.; Sneige, N., 2003:
Phase II chemoprevention trial of celecoxib using ductal lavage

Behin, A.; Friedman, H.; Faivre, S.; Carpentier, A.; Ould Kaci, M.; Delattre, J.Y.; Lokiec, F.; Weems, G.; Smith, S.; Raymond, E., 2002:
Phase II clinical and pharmacokinetic trial of irofulven in patients with recurrent malignant glioma Preliminary data

O'connor, O.A.; Wright, J.; Moskowitz, C.; Straus, D.; Macgregor Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A.D., 2003:
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent and mantle cell lymphomas

Calvert, A.H.; Thomas, H.; Colombo, N.; Gore, M.; Earl, H.; Sena, L.; Camboni, G.; Liati, P.; Sessa, C., 2001:
Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer

Anklesaria, P.S.; Gupta, A.S.; Rege, N.N.; Chogale, A.R.; Ashar, V.J.; Rajwade, N.A.; Desai, N.K.; Gaur, S.P.S.; Asthana, O.P.; Dahanukar, S.A., 2001:
Phase II clinical study of Picroliv in acute viral hepatitis

Cleary, J.D.; Gordon, R.; Chapman, S., 2003:
Phase II clinical trial of daclizumab/amphotericin B combination

Medioni, J.R.; D.R.cke, Y.; Asselain, B., 2000:
Phase II clinical trials in oncology Recommendations for choice of planification methods

Rutkowski, T.; Sasiadek, W.; Mucha, A.; Skladowski, K.; Sygula, M.; Golen, M.; Przeorek, W.; Pilecki, B., 2003:
Phase II continuous 7 days per week irradiation concomitantly with chemotherapy in advanced head and neck tumors treatment

Cobleigh, M.A.; Miller, K.D.; Langmuir, V.K.; Reimann, J.D.; Vassel, A.V.; Novotny, W.F.; Sledge, G.W., 2001:
Phase II dose escalation trial of AvastinTM in women with previously treated metastatic breast cancer

Jordan, A.; Juurlink, B.H.J., 1999:
Phase II enzyme activity and induction in astrocytes and oligodendrocytes

Talpur, R.; Apisarnthanarax, N.; Ward, S.; Herne, K.; Chiao, N.; Kurzrock, R.; Duvic, M., 2003:
Phase II evaluation of Gemcitabine as a single agent for cutaneous T-cell lymphoma

Anderson, E.L.; Belshe, R.B.; Newman, F.K.; Karron, R.; Wright, P.; Roberton, D.; Reisinger, K.; Henderson, F.; King, J.; Loh, R.; Sly, P.; Mcintyre, P.; Ziegler, J.; Keyserling, H.; Schwartz, R.; Weinberg, G.; Murphy, B.; Tatem, J.; Gohs, F.; Tsai, T., 2002:
Phase II evaluation of PIV3 cp45 live, attenuated parainfluenza type 3 vaccine in healthy children 6-18 months of age

Hebbar, M.; Tournigand, C.; Lledo, G.; Mabro, M.; Andre, T.; Aparicio, T.; Flesch, M.; Varette, A.; D.G.amont, A., 2001:
Phase II evaluation of an alternated FOLFOX/FOLFIRI regimen in patients with resistant metastatic colorectal cancer

Steger, G.G.; Wenzel, C.; Schmidinger, M.; Locker, G.J.; Rudas, M.; Taucher, S.; Gnant, M.; Jakesz, R., 1999:
Phase II evaluation of docetaxel and epidoxorubicin + G-CSF in primary and advanced breast cancer

Hayashi, K.; Ando, N.; Watanabe, H.; Ide, H.; Nagai, K.; Aoyama, N.; Takiyama, W.; Ishida, K.; Isono, K.; Makuuchi, H.; Imamura, M.; Shinoda, M.; Ikeuchi, S.; Kabuto, T.; Yamana, H.; Fukuda, H., 2001:
Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus A Japan Esophageal Oncology Group trial

Levin, Victor, A., 2000:
Phase II glioma trials with temozolomide combinations and other new agents

Cardenal, F.; Domine, M.; Massuti, B.; Felip, E.; Carrato, A.; Garrido, P.; Alberola, V.; Anton, A.; Barneto, I.; Rosell, R., 1999:
Phase II multi-institutional study of Irinotecan and Cisplatin on a three-week schedule in patients with advanced non-small cell lung cancer

Winer, E.; Cobleigh, M.; Dickler, M.; Miller, K.; Fehrenbacher, L.; Jones, C.; Justice, R., 2002:
Phase II multicenter study to evaluate the efficacy and safety of TarcevaTM in women with previously treated locally advanced or metastatic breast cancer

Loesch, D.M.; Robert, N.J.; Keller, A.M.; Young, J.A.; Rohrbaugh, T.M.; Smyth, A.C., 1999:
Phase II multicenter trial of a weekly paclitaxel, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer

Decaudin, D.; Etienne, M.C.ristine; D.C.emoux, P.; Maciorowski, Z.; Vantelon, J.M.rie; Voog, E.; Urien, S.; Tran Perennou, C.; Nemati, F.; Vedrine, L.; Vielh, P.; Pouillart, P., 2003:
Phase II multicenter trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma

Yunus, F.; George, S.; Smith, J.; Geils, G.S.; Geils, G.J., 2003:
Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated Non-Hodgkins Lymphoma

Yunus, F.; George, S.; Smith, J.; Geils, G.S.; Geils, G.J., 2003:
Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia

Mantovani, G.; Macciò, A.; Madeddu, C.; Serpe, R.; Antoni, G.; Massa, E.; Dessì, M.; Panzone, F., 2010:
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia

Balana, C.; Margeli, M.; Manzano, J.; Moran, T.; Font, A.; Abad, A.; Rosell, R., 2001:
Phase II of cisplatin , etoposide and gemcitabine in cancer of unknown primary

Sunkara,M.; Wells,M.J.M., 2010:
Phase II pharmaceutical metabolites acetaminophen glucuronide and acetaminophen sulfate in wastewater

Kahl, B.S.; Bailey, H.H.; Petroni, G.; Jaslowski, A.; Bayer, G.; Blank, J.; Bottner, W.; Mcgovern, J.; Smith, J.; Turman, N.; Werndli, J.; Longo, W.L., 2003:
Phase II pilot study of modified hyper-CVAD plus rituximab for previously untreated mantle cell lymphoma A Wisconsin oncology network Study

Powell, J.J.; Hill, G.; Storey, S.; Murchison, J.; Fearon, K.C.H.; Ross, J.A.; Siriwardena, A.K., 1999:
Phase II randomised controlled trial of early enteral nutrition in predicted severe acute pancreatitis

Oudard, S.; Banu, E.B.; Voog, E.; Hardy Bessard, H.; Linassier, C.; Beuzeuboc, P.; Banu, A., 2003:
Phase II randomised trial of docetaxel , estramustine and prednisone Two schedules - versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer

Duvic, M.; Talpur, R.; Ziari, S.; Persyn, D.; Stevens, V., 2004:
Phase II randomized bilateral comparison or bexarotene 1 % topical gel in alopecia areata

Hariharan, S.; Shapiro, W.; Chang, S.; Cohen, B.H.; Mechtler, L.; Carr, L., 2000:
Phase II randomized dose ranging trial of human corticotropin releasing factor in symptomatic brain tumor patients

Recchia, F.; D.F.lippis, S.; Rosselli, M.; Saggio, G.; Amiconi, G.; Cesta, A.; Fumagalli, L.; Rea, S.; Sica, G., 2002:
Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in advanced cancer

Ould Kaci, M.; Muracciole, X.; Vannetzel, J.M.; Mottet, N.; Culine, S.; D.P.lma, M.; Cvitkovic, E.; Dupont Andre, G.; Benoit, G.; Jardin, A., 1999:
Phase II randomized study of oxaliplatin , vs its combination with 5-FU in hormone refractory prostate cancer patients

Spicer, D.V.; Groshen, S.; Doroshow, J.H.; Synold, T.; Gandara, D.; Russell, C.; Muggia, F., 1999:
Phase II randomized study of paclitaxel and paclitaxel + PSC 833 for advanced breast cancer

Chan, S.; Johnston, S.; Scheulen, M.E.; Mross, K.; Berger, M.; Kirsch, T., 2002:
Phase II safety and activity trial of two dose levels of CCI-779 in women with previously treated locally advanced or metastatic cancer Interim report

Edelman, R.; Tacket, C.O.; Wasserman, S.S.; Bodison, S.A.; Perry, J.G.; Mangiafico, J.A., 2001:
Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218

Edelman, R.; Kublin, J.G.; Bodison, S.A.; Schmeckpeper, B.J.; Hamilton, R.G.; Kashala, O.; Diggs, C.L.; Nussenzweig, R.S.; Ansari, S.; Calvo Calle, J.M.; Oliveira, G.A.; Nardin, E.H., 1999:
Phase II safety phase I trial of a Plasmodium falciparum map vaccine in adult volunteers Immediate-type hypersensitivity reactions to the map vaccine

Jodrell, D.I.; Evans, T.R.J.; Steward, W.; Cameron, D.; Prendiville, J.; Aschele, C.; Noberasco, C.; Lind, M.; Carmichael, J.; Dobbs, N.; Camboni, G.; Gatti, B.; De Braud, F., 2004:
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma

Goldfarb, P.; Hill, F., 1999:
Phase II studies using electroporation therapy in patients with recurrent head and neck cancer A safe and active treatment approach

Szumacher, E.; Wighton, A.; Franssen, E.; Andersson, L.; Chow, E.; Ackerman, I.; Kim, J.; Wojcicka, A.; Tsao, M.; Ung, Y., 2000:
Phase II study assessing effectiveness of Biafine cream as a prophylactic agent for radiation induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant chemotherapy Preliminary results

Rivera, E.; Chevlen, E.; Eckardt, J.; Kennedy, M.J.; Sawhney, R.; Sutton, L.; Frye, D.; Hedrick, J.; Mcguirt, C.; Levin, J.; Hohneker, J.; Hortobagyi, G.N., 1999:
Phase II study evaluating the combination of eniluracil plus oral 5-fluorouracil as a 28-day regimen for the treatment of patients with taxane- and anthracycline-resistant advanced breast cancer Preliminary results

Jeanfaivre, T.; Chaleil, D.; Maillet, F.; Tuchais, E., 1999:
Phase II study evaluating the efficacy of the combination of a corticosteroid and a progestogen in the treatment of anorexia in patients with bronchogenic carcinoma

Pohlen, U.; Berger, G.; Buhr, H.J., 2002:
Phase II study for abdominal stop-flow perfusion A regional chemotherapy concept for nonresectable abdominal tumor manifestations

Issa, J.P.erre; Garcia Manero, G.; Talpaz, M.; Cortes, J.; Giles, F.; Verstovsek, S.; Faderl, S.; O'brien, S.; Morris, G.; Kantarjian, H., 2003:
Phase II study of 5-aza-2-deoxycytidine in patients with Philadelphia chromosome positive chronic myelogenous leukemia resistant or intolerant to imatinib mesylate

Scagliotti, G.; Shin, D.; Kindler, H.; Johnson, D.; Keppler, U., 2001:
Phase II study of ALIMTA single agent in patients with malignant pleural mesothelioma

Gotlib, J.; Jamieson, C.H.M.; List, A.; Cortes, J.; Albitar, M.; Sridhar, K.; Dugan, K.; Quesada, S.; Diaz, G.; Pate, O.; Novotny, W.; Chen, H.; Greenberg, P.L., 2003:
Phase II study of Bevacizumab in patients with myelodysplastic syndrome Preliminary results

Ajani, J.A.; Fairweather, J.; Pisters, P.; Feig, B.; Hargraves, K.; Charnsangavej, C., 2000:
Phase II study of CPT-11 and cisplatin in patients with advanced gastric carcinoma

Narahara, H.; Imamura, H.; Ikeda, M.; Kobayashi, K.; Fujitani, K.; Kato, M.; Iwamoto, H.; Takabayashi, A.; Tsukuma, H.; Tsujinaka, T.; Furukawa, H.; Taguchi, T., 2002:
Phase II study of CPT-11 plus CDDP in patients with metastatic gastric cancer

Faderl, B.; Von Pawel, J.; Wagner, H.; Krauss, C.; Achterrath, W., 1999:
Phase II study of Docetaxel and Cisplatin in a circadian timing as first line chemotherapy in advanced non small cell lung cancer

Piga, A.; Galanello, R.; Cappellini, M.D.; Forni, G.L.ca; Lupo, G.; Ford, J.M.; Sechaud, R.; Mueller, C.; Opitz, H.; Alberti, D., 2003:
Phase II study of ICL670, an oral chelator, in adult thalassaemia patients with transfusional iron overload Efficacy, safety, pharmacokinetics and pharmacodynamics after 18 months of therapy

Minasian, L.; Sarosy, G.; Dyer, V.; Kim, S.; Kohler, D.R.; Murgo, A.; Smith, S.; Figg, W.D.; Reed, E., 2000:
Phase II study of MGI-114 in platinum-resistant recurrent ovarian cancer

Hirte, H.; Oza, A.; Hoskins, P.; Ellard, S.; Grimshaw, R.; Dubuc Lissoir, J.; Kerr, I.; Fisher, B.; Seymour, L., 2003:
Phase II study of OSI-774 given in combination with carboplatin in patients with recurrent epithelial ovarian cancer NCIC ctg ind149

Swinnen, L.J.; Gaynor, E.; Leblanc, M.; Lechowicz, M.J.; Unger, J.; Miller, T.P.; Grogan, T.A.; Fisher, R.I., 2003:
Phase II study of ProMACE-CytaBOM with trimethoprim sulfamethoxazole, granulocyte colony stimulating factor and antiretroviral therapy in patients with AIDS related non Hodgkins lymphoma ,

Sakata, Yuh; Ohtsu, Atsushi; Baba, Hideo; Mitachi, Yasushi; Horikoshi, Noboru; Sugimachi, Keizo; Taguchi, Tetsuo, 1999:
Phase II study of S-1 in patients with advanced colorectal cancer